Heiner Wedemeyer

Heiner Wedemeyer's AcademicInfluence.com Rankings

Heiner Wedemeyer

Medical

#1345

World Rank

#1672

Historical Rank

Gastroenterology

#15

World Rank

#15

Historical Rank

medical Degrees

Heiner Wedemeyer

Philosophy

#4327

World Rank

#6801

Historical Rank

Logic

#1814

World Rank

#2657

Historical Rank

philosophy Degrees

Download Badge

Medical
Philosophy

Heiner Wedemeyer's Degrees

Doctorate Medicine Hannover Medical School
PhD Gastroenterology Hannover Medical School

Why Is Heiner Wedemeyer Influential?

(Suggest an Edit or Addition)

(See a Problem?)

Heiner Wedemeyer's Published Works

Number of citations in a given year to any of this author's works

Total number of citations to an author for the works they published in a given year. This highlights publication of the most important work(s) by the author

Published Works

Global prevalence and genotype distribution of hepatitis C virus infection in 2015: a modelling study. (2017) (1601)
Association between sustained virological response and all-cause mortality among patients with chronic hepatitis C and advanced hepatic fibrosis. (2012) (1468)
ABT-450/r-ombitasvir and dasabuvir with ribavirin for hepatitis C with cirrhosis. (2014) (904)
Treatment of acute hepatitis C with interferon alfa-2b. (2001) (823)
Treating viral hepatitis C: efficacy, side effects, and complications (2006) (697)
Impaired Effector Function of Hepatitis C Virus-Specific CD8+ T Cells in Chronic Hepatitis C Virus Infection1 (2002) (683)
Increased populations of regulatory T cells in peripheral blood of patients with hepatocellular carcinoma. (2005) (642)
Sustained Virologic Response and Clinical Outcomes in Patients with Chronic Hepatitis C and Advanced Fibrosis (2007) (618)
Tremelimumab in combination with ablation in patients with advanced hepatocellular carcinoma. (2017) (546)
Myeloid derived suppressor cells inhibit natural killer cells in patients with hepatocellular carcinoma via the NKp30 receptor (2009) (544)
Retreatment of HCV with ABT-450/r-ombitasvir and dasabuvir with ribavirin. (2014) (518)
EASL recommendations on treatment of hepatitis C - Final update of the series. (2020) (497)
The present and future disease burden of hepatitis C virus (HCV) infection with today's treatment paradigm (2014) (477)
Quantitative analysis of hepatitis C virus-specific CD8(+) T cells in peripheral blood and liver using peptide-MHC tetramers. (1999) (467)
Hepatitis B surface antigen (HBsAg) levels in the natural history of hepatitis B virus (HBV)-infection: a European perspective. (2010) (399)
Short-term antiviral efficacy of BILN 2061, a hepatitis C virus serine protease inhibitor, in hepatitis C genotype 1 patients. (2004) (346)
Long‐term efficacy of tenofovir monotherapy for hepatitis B virus‐monoinfected patients after failure of nucleoside/nucleotide analogues (2010) (346)
Epidemiology, pathogenesis and management of hepatitis D: update and challenges ahead (2010) (336)
EASL Clinical Practice Guidelines on hepatitis E virus infection. (2018) (329)
Glecaprevir–Pibrentasvir for 8 or 12 Weeks in HCV Genotype 1 or 3 Infection (2018) (324)
Hepatitis B surface antigen quantification: why and how to use it in 2011 - a core group report. (2011) (309)
Historical epidemiology of hepatitis C virus (HCV) in selected countries (2014) (295)
Treatment of chronic hepatitis D with the entry inhibitor myrcludex B: First results of a phase Ib/IIa study. (2016) (287)
Pathogenesis and treatment of hepatitis e virus infection. (2012) (279)
Increased risk of hepatocellular carcinoma among patients with hepatitis C cirrhosis and diabetes mellitus (2008) (270)
Hepatitis E virus infection (2017) (261)
The green tea polyphenol, epigallocatechin‐3‐gallate, inhibits hepatitis C virus entry (2011) (259)
Hepatitis delta virus (2011) (258)
Early monotherapy with pegylated interferon alpha‐2b for acute hepatitis C infection: The HEP‐NET acute‐HCV‐II study (2006) (253)
The state of hepatitis B and C in Europe: report from the hepatitis B and C summit conference * (2011) (245)
Cross-Reactivity between Hepatitis C Virus and Influenza A Virus Determinant-Specific Cytotoxic T Cells (2001) (244)
Natural history of acute and chronic hepatitis C. (2012) (235)
Expert opinion on the treatment of patients with chronic hepatitis C (2009) (232)
Food intake increases liver stiffness in patients with chronic or resolved hepatitis C virus infection (2009) (226)
Strategies to manage hepatitis C virus (HCV) disease burden (2014) (218)
Late HDV RNA relapse after peginterferon alpha‐based therapy of chronic hepatitis delta (2014) (217)
Kinetics of hepatitis B surface antigen decline during 3 years of telbivudine treatment in hepatitis B e antigen–positive patients (2010) (215)
Cutting Edge: Identification and Characterization of Human Intrahepatic CD49a+ NK Cells (2015) (213)
Safety and efficacy of lamivudine in patients with severe acute or fulminant hepatitis B, a multicenter experience (2006) (197)
Daclatasvir plus sofosbuvir, with or without ribavirin, achieved high sustained virological response rates in patients with HCV infection and advanced liver disease in a real-world cohort (2016) (197)
Hepatitis E virus infection as a cause of graft hepatitis in liver transplant recipients (2010) (192)
Impact of patatin‐like phospholipase‐3 (rs738409 C>G) polymorphism on fibrosis progression and steatosis in chronic hepatitis C (2011) (188)
Entecavir treatment does not eliminate the risk of hepatocellular carcinoma in chronic hepatitis B: limited role for risk scores in Caucasians (2014) (187)
Interferon-alpha-induced TRAIL on natural killer cells is associated with control of hepatitis C virus infection. (2010) (186)
[Prophylaxis, diagnosis and therapy of hepatitis C virus (HCV) infection: the German guidelines on the management of HCV infection]. (2018) (185)
Inhibition of hepatitis B virus replication in vivo by nucleoside analogues and siRNA. (2003) (185)
Antiviral efficacy of NS3‐serine protease inhibitor BILN‐2061 in patients with chronic genotype 2 and 3 hepatitis C (2005) (184)
[Prophylaxis, diagnosis and therapy of hepatitis B virus infection - the German guideline]. (2011) (181)
Virological response to entecavir is associated with a better clinical outcome in chronic hepatitis B patients with cirrhosis (2012) (174)
A mutation in the hepatitis E virus RNA polymerase promotes its replication and associates with ribavirin treatment failure in organ transplant recipients. (2014) (167)
Entecavir treatment for chronic hepatitis B: Adaptation is not needed for the majority of naïve patients with a partial virological response (2011) (167)
Peginterferon plus adefovir versus either drug alone for hepatitis delta. (2011) (163)
Hepatitis C virus mutation affects proteasomal epitope processing. (2004) (160)
Therapeutic vaccination of chronic hepatitis C nonresponder patients with the peptide vaccine IC41. (2008) (157)
Ribavirin treatment of acute and chronic hepatitis E: a single‐centre experience (2013) (155)
Hepatitis D virus infection—Not a vanishing disease in Europe! (2007) (149)
Telomerase gene mutations are associated with cirrhosis formation (2011) (146)
Chronic Hepatitis E in Heart Transplant Recipients (2012) (146)
Hepatitis E virus (HEV)‐specific T‐cell responses are associated with control of HEV infection (2012) (146)
Progress in the development of preventive and therapeutic vaccines for hepatitis C virus. (2011) (145)
Clinical feasibility of liver elastography by acoustic radiation force impulse imaging (ARFI). (2011) (139)
Nonreversible MAIT cell‐dysfunction in chronic hepatitis C virus infection despite successful interferon‐free therapy (2016) (138)
In vivo evidence for ribavirin-induced mutagenesis of the hepatitis E virus genome (2016) (136)
High rate of spontaneous clearance of acute hepatitis C virus genotype 3 infection (2004) (131)
Cytotoxic CD4+ T cells in viral hepatitis (2006) (131)
Entecavir plus tenofovir combination as rescue therapy in pre-treated chronic hepatitis B patients: an international multicenter cohort study. (2012) (125)
Guidance for Design and Endpoints of Clinical Trials in Chronic Hepatitis B—Report From the 2019 EASL‐AASLD HBV Treatment Endpoints Conference (2019) (122)
Estimates on HCV disease burden worldwide – filling the gaps (2015) (120)
Treatment of chronic hepatitis B. (2010) (120)
Antiviral effect of entecavir in chronic hepatitis B: influence of prior exposure to nucleos(t)ide analogues. (2010) (118)
Cyclosporine A inhibits hepatitis C virus nonstructural protein 2 through cyclophilin A (2009) (118)
Dual Function of the NK Cell Receptor 2B4 (CD244) in the Regulation of HCV-Specific CD8+ T Cells (2011) (113)
Clinical management of drug-drug interactions in HCV therapy: challenges and solutions. (2013) (113)
Direct ex vivo analysis of dendritic cells in patients with hepatocellular carcinoma. (2006) (113)
Hepatitis B core-related antigen (HBcrAg) levels in the natural history of hepatitis B virus infection in a large European cohort predominantly infected with genotypes A and D. (2015) (112)
Viral and Host Responses After Stopping Long-term Nucleos(t)ide Analogue Therapy in HBeAg-Negative Chronic Hepatitis B. (2016) (111)
Management of viral hepatitis in patients with haematological malignancy and in patients undergoing haemopoietic stem cell transplantation: recommendations of the 5th European Conference on Infections in Leukaemia (ECIL-5). (2016) (110)
Direct-Acting Antiviral-Induced Hepatitis C Virus Clearance Does Not Completely Restore the Altered Cytokine and Chemokine Milieu in Patients With Chronic Hepatitis C. (2016) (108)
Repopulation efficiencies of adult hepatocytes, fetal liver progenitor cells, and embryonic stem cell-derived hepatic cells in albumin-promoter-enhancer urokinase-type plasminogen activator mice. (2009) (107)
Ledipasvir plus sofosbuvir fixed-dose combination for 6 weeks in patients with acute hepatitis C virus genotype 1 monoinfection (HepNet Acute HCV IV): an open-label, single-arm, phase 2 study. (2017) (106)
The impact of hepatitis E in the liver transplant setting. (2014) (105)
The HEP-NET B/C co-infection trial: A prospective multicenter study to investigate the efficacy of pegylated interferon-alpha2b and ribavirin in patients with HBV/HCV co-infection. (2008) (104)
Eligibility and Safety of Triple Therapy for Hepatitis C: Lessons Learned from the First Experience in a Real World Setting (2013) (103)
Compromised function of natural killer cells in acute and chronic viral hepatitis. (2014) (103)
Improvement of liver function parameters in advanced HCV‐associated liver cirrhosis by IFN‐free antiviral therapies (2015) (100)
Prophylaxis, diagnosis and therapy of hepatitis B virus (HBV) infection: the German guidelines for the management of HBV infection. (2007) (99)
Final results of a multicenter, open-label phase 2b clinical trial to assess safety and efficacy of Myrcludex B in combination with Tenofovir in patients with chronic HBV/HDV co-infection (2018) (98)
Epitope mapping of cytochrome P4502D6 autoantigen in patients with chronic hepatitis C during alpha-interferon treatment. (1999) (97)
Quantitative HBsAg and HDV‐RNA levels in chronic delta hepatitis (2010) (97)
Long‐term follow‐up after successful interferon therapy of acute hepatitis C (2004) (97)
Virological and clinical characteristics of delta hepatitis in Central Europe (2009) (96)
Delayed versus immediate treatment for patients with acute hepatitis C: a randomised controlled non-inferiority trial. (2013) (96)
Epidemiological trends in incidence and mortality of hepatobiliary cancers in Germany (2011) (95)
Performance and clinical utility of a novel fully automated quantitative HCV-core antigen assay. (2009) (95)
Life expectancy in patients with chronic HCV infection and cirrhosis compared with a general population. (2014) (94)
Drug-Drug Interactions With Novel All Oral Interferon-Free Antiviral Agents in a Large Real-World Cohort. (2016) (93)
Deep Sequencing Reveals Mutagenic Effects of Ribavirin during Monotherapy of Hepatitis C Virus Genotype 1-Infected Patients (2013) (91)
Rituximab as rescue therapy in anti-neutrophil cytoplasmic antibody-associated vasculitis: a single-centre experience with 15 patients. (2008) (89)
Correlation between the Elecsys HBsAg II assay and the Architect assay for the quantification of hepatitis B surface antigen (HBsAg) in the serum. (2011) (88)
How stable is the hepatitis C virus (HCV)? Environmental stability of HCV and its susceptibility to chemical biocides. (2010) (86)
Extra‐hepatic replication and infection of hepatitis E virus in neuronal‐derived cells (2016) (86)
Establishment of a Novel Quantitative Hepatitis D Virus (HDV) RNA Assay Using the Cobas TaqMan Platform To Study HDV RNA Kinetics (2010) (85)
Treatment of chronic hepatitis C with PEGylated interferon and ribavirin (2002) (83)
Hepatitis B virus-specific T cell responses after stopping nucleos(t)ide analogue therapy in HBeAg-negative chronic hepatitis B. (2018) (81)
Treatment with daily consensus interferon (CIFN) plus ribavirin in non-responder patients with chronic hepatitis C: a randomized open-label pilot study. (2006) (81)
Prothrombotic immune thrombocytopenia after COVID-19 vaccine (2021) (80)
Hepatitis E in Germany--an under-reported infectious disease. (2014) (79)
Glucocorticosteroids increase cell entry by hepatitis C virus. (2010) (79)
A Decline in Hepatitis B virus Surface Antigen (HBsAg) Predicts Clearance, but does not Correlate with Quantitative HBeAg or HBV DNA Levels (2008) (78)
Hepatitis B Surface Antigen (Hbsag) Decrease and Serum Interferon-Inducible Protein-10 Levels as Predictive Markers for Hbsag Loss during Treatment with Nucleoside/Nucleotide Analogues (2011) (78)
Prognostic implications of lactate, bilirubin, and etiology in German patients with acute liver failure. (2008) (78)
Antiviral treatment and liver‐related complications in hepatitis delta (2017) (76)
Global multi-stakeholder endorsement of the MAFLD definition. (2022) (74)
The role of zinc in liver cirrhosis. (2015) (74)
Initial presentation of acute hepatitis C virus (HCV) infection among HIV-negative and HIV-positive individuals-experience from 2 large German networks on the study of acute HCV infection. (2009) (73)
Managing HBV in patients with impaired immunity (2010) (72)
Induction of autoantibodies to the adrenal cortex and pancreatic islet cells by interferon alpha therapy for chronic hepatitis C (2001) (71)
Peginterferon alfa-2a plus tenofovir disoproxil fumarate for hepatitis D (HIDIT-II): a randomised, placebo controlled, phase 2 trial. (2019) (71)
Treatment Options for Hepatitis Delta Virus Infection (2013) (71)
Hepatitis C: The beginning of the end—key elements for successful European and national strategies to eliminate HCV in Europe (2018) (70)
Generation of Human Antigen-Specific Monoclonal IgM Antibodies Using Vaccinated “Human Immune System” Mice (2010) (68)
[Prophylaxis, Diagnosis and Therapy of Hepatitis-B-Virus-(HBV-)Infection: upgrade of the guideline, AWMF-Register 021/011]. (2007) (68)
Therapeutic vaccine IC41 as late add-on to standard treatment in patients with chronic hepatitis C. (2009) (67)
Treating chronic hepatitis delta: The need for surrogate markers of treatment efficacy. (2019) (67)
Recommendations for the management of hepatitis C virus infection among people who inject drugs. (2013) (67)
Intestinal microbiota in patients with chronic hepatitis C with and without cirrhosis compared with healthy controls (2018) (66)
GS-13-Final results of a multicenter, open-label phase 2 clinical trial (MYR203) to assess safety and efficacy of myrcludex B in cwith PEG-interferon Alpha 2a in patients with chronic HBV/HDV co-infection (2019) (66)
Late hepatitis B virus relapse in patients co-infected with hepatitis B virus and hepatitis C virus after antiviral treatment with pegylated interferon-a2b and ribavirin (2009) (65)
Increased HEV Seroprevalence in Patients with Autoimmune Hepatitis (2014) (65)
Proteoglycans Act as Cellular Hepatitis Delta Virus Attachment Receptors (2013) (65)
Direct‐acting antiviral treatment of chronic HCV‐infected patients on opioid substitution therapy: Still a concern in clinical practice? (2018) (64)
Prothrombotic immune thrombocytopenia after COVID-19 vaccination (2021) (63)
[Expert opinion on boceprevir- and telaprevir-based triple therapies of chronic hepatitis C]. (2012) (63)
Clinical value of on-treatment HCV RNA levels during different sofosbuvir-based antiviral regimens. (2016) (62)
Oral immunization with HCV-NS3-transformed Salmonella: induction of HCV-specific CTL in a transgenic mouse model. (2001) (61)
Role of a cirrhosis risk score for the early prediction of fibrosis progression in hepatitis C patients with minimal liver disease. (2009) (61)
Glycyrrhizin in patients who failed previous interferon alpha-based therapies: biochemical and histological effects after 52 weeks (2012) (61)
Clinical and virological heterogeneity of hepatitis delta in different regions world‐wide: The Hepatitis Delta International Network (HDIN) (2018) (60)
Effects of ribavirin dose reduction vs erythropoietin for boceprevir-related anemia in patients with chronic hepatitis C virus genotype 1 infection--a randomized trial. (2013) (60)
Antiviral Activities of Different Interferon Types and Subtypes against Hepatitis E Virus Replication (2016) (59)
Safety and Effectiveness of Direct-Acting Antiviral Agents for Treatment of Patients With Chronic Hepatitis C Virus Infection and Cirrhosis. (2016) (59)
Rapid early HDV RNA decline in the peripheral blood but prolonged intrahepatic hepatitis delta antigen persistence after liver transplantation. (2012) (59)
Chronic hepatitis C virus infection irreversibly impacts human natural killer cell repertoire diversity (2018) (58)
Clinical Utility of HCV Core Antigen Detection and Quantification in the Diagnosis and Management of Patients with Chronic Hepatitis C Receiving an All-Oral, Interferon-Free Regimen (2016) (57)
Long-term outcome of chronic hepatitis B in heart transplant recipients. (1998) (57)
Association Between Level of Hepatitis D Virus RNA at Week 24 of Pegylated Interferon Therapy and Outcome. (2015) (57)
Prevalence of HBV genotypes in Central and Eastern Europe (2008) (56)
Reduced dose and duration of peginterferon alfa-2b and weight-based ribavirin in patients with genotype 2 and 3 chronic hepatitis C. (2011) (55)
Re-emerging interest in hepatitis delta: new insights into the dynamic interplay between HBV and HDV. (2010) (54)
Hepatitis B Virus e Antigen Loss during Adefovir Dipivoxil Therapy Is Associated with Enhanced Virus-Specific CD4+ T-Cell Reactivity (2007) (54)
A phase 2 dose-escalation study of lonafarnib plus ritonavir in patients with chronic hepatitis D: final results from the Lonafarnib with ritonavir in HDV-4 (LOWR HDV-4) study (2017) (54)
Safety and on-treatment efficacy of telaprevir: the early access programme for patients with advanced hepatitis C (2013) (53)
Telbivudine plus pegylated interferon alfa-2a in a randomized study in chronic hepatitis B is associated with an unexpected high rate of peripheral neuropathy. (2015) (53)
Hepatitis D revival (2011) (53)
Interferon‐free therapy of chronic hepatitis C with direct‐acting antivirals does not change the short‐term risk for de novo hepatocellular carcinoma in patients with liver cirrhosis (2018) (53)
Hepatitis A virus infection suppresses hepatitis C virus replication and may lead to clearance of HCV. (2006) (52)
Clinical outcomes following DAA therapy in patients with HCV-related cirrhosis depend on disease severity. (2020) (52)
Hepatitis E Virus Mutations: Functional and Clinical Relevance (2016) (52)
Influence of different frequencies and insertion depths on the diagnostic accuracy of liver elastography by acoustic radiation force impulse imaging (ARFI). (2013) (51)
Increased NK Cell Function After Cessation of Long-Term Nucleos(t)ide Analogue Treatment in Chronic Hepatitis B Is Associated With Liver Damage and HBsAg Loss (2018) (51)
Barriers to care and treatment for patients with chronic viral hepatitis in Europe: a systematic review (2014) (51)
O4 PROLONGED THERAPY OF HEPATITIS DELTA FOR 96 WEEKS WITH PEGYLATED-INTERFERON-α-2a PLUS TENOFOVIR OR PLACEBO DOES NOT PREVENT HDVRNA RELAPSE AFTER TREATMENT: THE HIDIT-2 STUDY (2014) (51)
Improvement of platelets after SVR among patients with chronic HCV infection and advanced hepatic fibrosis (2016) (51)
Treatment of HBV/HCV coinfection (2010) (51)
Influenza virus infection as precipitating event of acute-on-chronic liver failure. (2019) (51)
Hepatitis B virus immunization with an adjuvant containing vaccine after liver transplantation for hepatitis B‐related disease: failure of humoral and cellular immune response (2006) (51)
Dominance of hepatitis C virus (HCV) is associated with lower quantitative hepatitis B surface antigen and higher serum interferon-γ-induced protein 10 levels in HBV/HCV-coinfected patients. (2015) (51)
A heterogeneous hierarchy of co-regulatory receptors regulates exhaustion of HCV-specific CD8 T cells in patients with chronic hepatitis C. (2015) (51)
Chronic hepatitis delta virus infection leads to functional impairment and severe loss of MAIT cells. (2019) (51)
Treatment of acute hepatitis C: the success of monotherapy with (pegylated) interferon alpha. (2008) (51)
HEV-associated cryoglobulinaemia and extrahepatic manifestations of hepatitis E. (2014) (50)
Global real‐world evidence of sofosbuvir/velpatasvir as simple, effective HCV treatment: Analysis of 5552 patients from 12 cohorts (2020) (49)
Peptide-beta2-microglobulin-MHC fusion molecules bind antigen-specific T cells and can be used for multivalent MHC-Ig complexes. (2002) (49)
1419 A RANDOMIZED TRIAL COMPARING RIBAVIRIN DOSE REDUCTION VERSUS ERYTHROPOIETIN FOR ANEMIA MANAGEMENT IN PREVIOUSLY UNTREATED PATIENTS WITH CHRONIC HEPATITIS C RECEIVING BOCEPREVIR PLUS PEGINTERFERON/RIBAVIRIN (2012) (49)
Hepatitis Delta: Immunopathogenesis and Clinical Challenges (2010) (49)
Real-world effectiveness of 8-week treatment with ledipasvir/sofosbuvir in chronic hepatitis C. (2017) (49)
[Diagnosis of and therapy for hepatocellular carcinoma]. (2013) (49)
HCV core antigen as an alternative to HCV RNA testing in the era of direct-acting antivirals: retrospective screening and diagnostic cohort studies. (2018) (48)
PROPEL: A randomized trial of mericitabine plus peginterferon alpha‐2a/ribavirin therapy in treatment‐naïve HCV genotype 1/4 patients (2013) (47)
Development and evaluation of a baseline-event-anticipation score for hepatitis delta (2014) (47)
Real‐world experience with the all‐oral, interferon‐free regimen of ombitasvir/paritaprevir/ritonavir and dasabuvir for the treatment of chronic hepatitis C virus infection in the German Hepatitis C Registry (2017) (47)
Immunopathogenesis of Hepatitis E Virus Infection (2013) (47)
Boceprevir, an NS3 serine protease inhibitor of hepatitis C virus, for the treatment of HCV infection. (2009) (46)
Hepatitis E Virus (HEV) ORF2 Antigen Levels Differentiate Between Acute and Chronic HEV Infection. (2016) (46)
Hepatitis B Surface Antigen Concentrations in Patients with HIV/HBV Co-Infection (2012) (46)
Human CCR4+CCR6+Th17 Cells Suppress Autologous CD8+ T Cell Responses (2012) (46)
Is there sufficient evidence to recommend antiviral therapy in hepatitis C? (2014) (46)
Impact of Intra- and Interspecies Variation of Occludin on Its Function as Coreceptor for Authentic Hepatitis C Virus Particles (2011) (46)
Hepatitis E in HIV‐positive patients in a low‐endemic country (2009) (45)
Elimination of Hepatitis C Virus has limited impact on the functional and mitochondrial impairment of HCV-specific CD8+ T cell responses. (2019) (45)
Clearance of low levels of HCV viremia in the absence of a strong adaptive immune response (2007) (45)
HBeAg‐positive hepatitis delta: virological patterns and clinical long‐term outcome (2012) (45)
1405 ALISPORIVIR PLUS RIBAVIRIN IS HIGHLY EFFECTIVE AS INTERFERON-FREE OR INTERFERON-ADD-ON REGIMEN IN PREVIOUSLY UNTREATED HCV-GT2 OR GT3 PATIENTS: SVR12 RESULTS FROM VITAL-1 PHASE 2B STUDY (2012) (44)
Hepatitis E Virus Infection: Circulation, Molecular Epidemiology, and Impact on Global Health (2020) (44)
The clinical significance of drug–drug interactions in the era of direct‐acting anti‐viral agents against chronic hepatitis C (2013) (44)
The role of zinc in liver cirrhosis. (2016) (44)
Whom? When? How? Another piece of evidence for early treatment of acute hepatitis C (2004) (44)
Aflatoxin and viral hepatitis exposures in Guatemala: Molecular biomarkers reveal a unique profile of risk factors in a region of high liver cancer incidence (2017) (44)
Functional and phenotypic characterization of peptide-vaccine-induced HCV-specific CD8+ T cells in healthy individuals and chronic hepatitis C patients. (2007) (44)
Caspase activation is required for antiviral treatment response in chronic hepatitis C virus infection (2006) (44)
Chronic hepatitis E in hematopoietic stem cell transplant patients in a low‐endemic country? (2012) (44)
Immunosuppression, liver injury and post‐transplant HCV recurrence (2012) (44)
Effects of HDV infection and pegylated interferon α treatment on the natural killer cell compartment in chronically infected individuals (2014) (43)
Efficacy and safety of sofosbuvir/ledipasvir for the treatment of patients with hepatitis C virus re‐infection after liver transplantation (2016) (43)
Alisporivir plus ribavirin, interferon free or in combination with pegylated interferon, for hepatitis C virus genotype 2 or 3 infection (2015) (43)
Prevalence of hepatitis C in a German prison for young men in relation to country of birth (2006) (43)
Cross-genotype-reactivity of the immunodominant HCV CD8 T-cell epitope NS3-1073. (2008) (43)
Induction of hepatitis C virus (HCV)‐specific T cells by needle stick injury in the absence of HCV‐viraemia (2007) (43)
Anti-HDV IgM as a Marker of Disease Activity in Hepatitis Delta (2014) (42)
Hepatitis E seroprevalence in the Americas: A systematic review and meta‐analysis (2018) (42)
Importance of very early HCV RNA kinetics for prediction of treatment outcome of highly effective all oral direct acting antiviral combination therapy. (2015) (41)
Multicenter Evaluation of the Elecsys Hepatitis B Surface Antigen Quantitative Assay (2011) (41)
Interferon α-stimulated natural killer cells from patients with acute hepatitis C virus (HCV) infection recognize HCV-infected and uninfected hepatoma cells via DNAX accessory molecule-1. (2012) (41)
Real-world effectiveness and safety of glecaprevir/pibrentasvir for the treatment of patients with chronic HCV infection: a meta-analysis. (2020) (41)
Aktualisierung der S3-Leitlinie zur Prophylaxe, Diagnostik und Therapie der Hepatitis-B-Virusinfektion AWMF-Register-Nr.: 021/011 Prophylaxis, Diagnosis and Therapy of Hepatitis B Virus Infection - (2011) (41)
Real‐world effectiveness of ombitasvir/paritaprevir/ritonavir±dasabuvir±ribavirin in patients with hepatitis C virus genotype 1 or 4 infection: A meta‐analysis (2017) (40)
Measurement of IgG4 in bile: a new approach for the diagnosis of IgG4-associated cholangiopathy (2012) (40)
High prevalence of hepatitis markers in immigrant populations: a prospective screening approach in a real-world setting (2014) (39)
Peg-Interferon Lambda Treatment Induces Robust Innate and Adaptive Immunity in Chronic Hepatitis B Patients (2017) (39)
Chronic hepatitis E in liver transplant recipients: a significant clinical problem? (2010) (39)
The German Hep-Net acute hepatitis C cohort: impact of viral and host factors on the initial presentation of acute hepatitis C virus infection. (2009) (39)
ARFI elastography of the spleen is inferior to liver elastography for the detection of portal hypertension. (2011) (39)
Sequence variations in HCV core-derived epitopes alter binding of KIR2DL3 to HLA-C∗03:04 and modulate NK cell function. (2016) (38)
Clearance of Chronic HCV Infection During Acute Delta Hepatitis (2009) (38)
Course and treatment of chronic hepatitis E virus infection in lung transplant recipients (2014) (38)
Hepatitis D virus‐specific cytokine responses in patients with chronic hepatitis delta before and during interferon alfa‐treatment (2011) (38)
Clinical Relevance of Transjugular Liver Biopsy in Comparison with Percutaneous and Laparoscopic Liver Biopsy (2009) (37)
PREDICTION OF SUSTAINED RESPONSE AFTER NUCLEO(S)TIDE ANALOGUE CESSATION USING HBSAG AND HBCRAG LEVELS - A MULTICENTER STUDY (CREATE). (2020) (37)
HBsAg kinetics in chronic hepatitis D during interferon therapy: on‐treatment prediction of response (2016) (37)
1054 SAFETY, PHARMACOKINETICS AND ANTIVIRAL EFFECT OF BI 207127, A NOVEL HCV RNA POLYMERASE INHIBITOR, AFTER 5 DAYS ORAL TREATMENT IN PATIENTS WITH CHRONIC HEPATITIS C (2007) (37)
HCV core antigen testing in HIV- and HBV-coinfected patients, and in HCV-infected patients on hemodialysis. (2012) (37)
Hepatitis E virus infection: multiple faces of an underestimated problem. (2013) (36)
Enrichment of Regulatory T Cells in Acutely Rejected Human Liver Allografts (2012) (36)
Reliable prediction of clinical outcome in patients with chronic HCV infection and compensated advanced hepatic fibrosis: a validated model using objective and readily available clinical parameters (2014) (36)
Isolated anti-HBV core phenotype in anti-HCV-positive patients is associated with hepatitis C virus replication. (2004) (36)
Seroprevalence of antibodies and antigens against hepatitis A–E viruses in refugees and asylum seekers in Germany in 2015 (2017) (36)
Immunoregulation of dendritic and T cells by alpha-fetoprotein in patients with hepatocellular carcinoma. (2004) (36)
Persistent neuropsychiatric impairment in HCV patients despite clearance of the virus?! (2017) (35)
Hepatitis E virus replication and interferon responses in human placental cells (2018) (35)
136 Antiviral effect of BILN 2061, a novel HCV serine protease inhibitor, after oral treatment over 2 days in patients with chronic hepatitis C, non-genotype 1 (2003) (35)
Hepatitis C virus enters human peripheral neuroblastoma cells – evidence for extra‐hepatic cells sustaining hepatitis C virus penetration (2011) (35)
a proof-of-concept Phase 2a clinical trial with Hbv/hdv entry inhibitor Myrcludex B : lb-20 (2014) (35)
S3-Leitlinie „Prophylaxe, Diagnostik und Therapie der Hepatitis-C-Virus (HCV) -Infektion“ (2018) (34)
Recommendations for standardized nomenclature and definitions of viral response in trials of hepatitis C virus investigational agents (2012) (34)
Frequency of very low HCV viremia detected by a highly sensitive HCV-RNA assay. (2007) (34)
Medication Adherence among Patients with Chronic Diseases: a Survey Based Study in Pharmacies. (2019) (34)
The German guideline for the management of hepatitis B virus infection: short version * (2008) (34)
Sustained virological response with telaprevir in 1,078 patients with advanced hepatitis C: the international telaprevir access program. (2014) (33)
Results of single‐center screening for chronic hepatitis E in children after liver transplantation and report on successful treatment with ribavirin (2013) (33)
Efficacy of immunotherapy with TG4040, peg-interferon, and ribavirin in a Phase 2 study of patients with chronic HCV infection. (2014) (33)
48 weeks of high dose (10 mg) bulevirtide as monotherapy or with peginterferon alfa-2a in patients with chronic HBV/HDV co-infection (2020) (33)
Improvement of liver function parameters in advanced HCV-associated liver cirrhosis by IFN-free antiviral therapies (2015) (32)
Hepatocytes that express variants of cyclophilin A are resistant to HCV infection and replication. (2012) (32)
Low Free Triiodothyronine Is Associated with Advanced Fibrosis in Patients at High Risk for Nonalcoholic Steatohepatitis (2019) (31)
High Prevalence and Significance of Hepatitis D Virus Infection among Treatment-Naïve HBsAg-Positive Patients in Northern Vietnam (2013) (31)
Chronic Hepatitis E in Rheumatology and Internal Medicine Patients: A Retrospective Multicenter European Cohort Study (2019) (31)
Impact of RAS mutation subtype on clinical outcome—a cross-entity comparison of patients with advanced non-small cell lung cancer and colorectal cancer (2018) (31)
How to diagnose and manage hepatic encephalopathy: a consensus statement on roles and responsibilities beyond the liver specialist (2015) (31)
Contrasting Timing of Virological Relapse After Discontinuation of Tenofovir or Entecavir in Hepatitis B e Antigen–Negative Patients (2018) (31)
Persistence of occult hepatitis B after removal of the hepatitis B virus-infected liver. (2008) (31)
Treatment of hepatitis B in special patient groups: hemodialysis, heart and renal transplant, fulminant hepatitis, hepatitis B virus reactivation. (2003) (31)
Creating an effective clinical registry for rare diseases (2016) (31)
Devil hepatitis D: an orphan disease or largely underdiagnosed? (2018) (31)
HCV core antigen as an alternate test to HCV RNA for assessment of virologic responses to all-oral, interferon-free treatment in HCV genotype 1 infected patients. (2017) (30)
Hepatitis E: an emerging infectious disease in Germany? (2011) (30)
Frequency, Private Specificity, and Cross-Reactivity of Preexisting Hepatitis C Virus (HCV)-Specific CD8+ T Cells in HCV-Seronegative Individuals: Implications for Vaccine Responses (2015) (30)
[Injuries from needles contaminated with hepatitis C virus: how high is the risk of seroconversion for medical personnel really?]. (2007) (30)
Hepatitis E virus infection in a hematopoietic stem cell donor (2014) (30)
The German network of excellence for viral hepatitis (Hep‐Net) (2003) (30)
Mutations in Hepatitis D Virus Allow It to Escape Detection by CD8+ T Cells and Evolve at the Population Level (2019) (30)
Detection of low HCV viraemia by repeated HCV RNA testing predicts treatment failure to triple therapy with telaprevir (2014) (30)
Evaluation of Sound Speed for Detection of Liver Fibrosis (2010) (30)
Genetic Immunization of Wild-Type and Hepatitis C Virus Transgenic Mice Reveals a Hierarchy of Cellular Immune Response and Tolerance Induction against Hepatitis C Virus Structural Proteins (2001) (30)
Long‐Term Study of Hepatitis Delta Virus Infection at Secondary Care Centers: The Impact of Viremia on Liver‐Related Outcomes (2020) (29)
High intrahepatic HHV-6 virus loads but neither CMV nor EBV are associated with decreased graft survival after diagnosis of graft hepatitis. (2012) (29)
HEV-specific T-cell responses are associated with control of HEV infection (2012) (29)
Antiviral therapy of hepatitis delta virus infection - progress and challenges towards cure. (2016) (29)
Successful early sofosbuvir‐based antiviral treatment after transplantation of kidneys from HCV‐viremic donors into HCV‐negative recipients (2019) (29)
Intravenous ketamine and progressive cholangiopathy in COVID-19 patients (2021) (29)
HCC Immune Surveillance and Antiviral Therapy of Hepatitis C Virus Infection (2018) (28)
Medical procedures as a risk factor for HCV infection in developed countries: do we neglect a significant problem in medical care? (2008) (28)
Immediate vs. delayed treatment in patients with acute hepatitis C based on IL28B polymorphism: a model-based analysis. (2012) (27)
Anti-HBc seroconversion after transplantation of anti-HBc positive nonliver organs to anti-HBc negative recipients. (2006) (27)
The New Era of Interferon-Free Treatment of Chronic Hepatitis C (2015) (27)
Non‐invasive fibrosis score for hepatitis delta (2017) (27)
Effect of peptide pools on effector functions of antigen-specific CD8+ T cells. (2009) (27)
Probability of HBsAg loss after nucleo(s)tide analogue withdrawal depends on HBV genotype and viral antigen levels. (2022) (26)
Hepatitis C and the leptin system: bound leptin levels are elevated in patients with hepatitis C and decrease during antiviral therapy. (2001) (26)
Hepatitis C virus core antigen testing in liver and kidney transplant recipients (2014) (26)
Kinetics of hepatitis C viral RNA and HCV‐antigen during dialysis sessions: Evidence for differential viral load reduction on dialysis (2008) (26)
New protease inhibitors and direct-acting antivirals for hepatitis C: interferon's long goodbye (2012) (26)
Home-based drainage of refractory ascites by a permanent-tunneled peritoneal catheter can safely replace large-volume paracentesis. (2017) (26)
Anti-Hdv Immunoglobulin M Testing in Hepatitis Delta Revisited: Correlations with Disease Activity and Response to Pegylated Interferon-α2A Treatment (2012) (26)
Prophylaxe, Diagnostik und Therapie der Hepatitis-C-Virus(HCV)-Infektion (2020) (25)
Applicability of Hepatitis C Virus RNA Viral Load Thresholds for 8-Week Treatments in Patients With Chronic Hepatitis C Virus Genotype 1 Infection. (2016) (25)
The comprehensive outcomes of hepatitis C virus infection: A multi‐faceted chronic disease (2018) (25)
Efficacy and tolerance of a combination of tenofovir disoproxil fumarate plus emtricitabine in patients with chronic hepatitis B: a European multicenter study. (2011) (25)
Successful treatment of fulminant hepatitis B during pregnancy. (2009) (25)
Hepatology - A Clinical Textbook, Fifth Edition (2014) (25)
Treg-specific IL-2 therapy can reestablish intrahepatic immune regulation in autoimmune hepatitis. (2020) (25)
Type I Interferon Elevates Co-Regulatory Receptor Expression on CMV- and EBV-Specific CD8 T Cells in Chronic Hepatitis C (2015) (25)
Chronic hepatitis E virus infection beyond transplantation or human immunodeficiency virus infection (2014) (25)
Eligibility and safety of the first interferon‐free therapy against hepatitis C in a real‐world setting (2015) (25)
Hepatitis E virus-induced primary cutaneous CD30(+) T cell lymphoproliferative disorder. (2017) (25)
Limited effectiveness and safety profile of protease inhibitor-based triple therapy against chronic hepatitis C in a real-world cohort with a high proportion of advanced liver disease (2014) (25)
The predictive value of IL28B gene polymorphism for spontaneous clearance in a single source outbreak cohort is limited in patients carrying the CCR5Δ32 mutation. (2011) (25)
[S3 guideline hepatitis C addendum]. (2015) (25)
Early assessment of safety and efficacy of tropifexor, a potent non bile-acid FXR agonist, in patients with primary biliary cholangitis: An interim analysis of an ongoing phase 2 study (2018) (24)
In vitro stimulation with HBV therapeutic vaccine candidate Nasvac activates B and T cells from chronic hepatitis B patients and healthy donors. (2015) (24)
Diagnostic algorithm for chronic hepatitis C virus infection: role of the new HCV-core antigen assay. (2005) (24)
Prevalence of Hepatitis B, C, and D in Germany: Results From a Scoping Review (2020) (24)
The case for simplifying and using absolute targets for viral hepatitis elimination goals (2020) (24)
Impact of HBsAg and HBcrAg levels on phenotype and function of HBV-specific T cells in patients with chronic hepatitis B virus infection (2021) (24)
Steroid treatment for severe acute cryptogenic hepatitis. (2007) (24)
Cytomegalovirus-Driven Adaptive-Like Natural Killer Cell Expansions Are Unaffected by Concurrent Chronic Hepatitis Virus Infections (2017) (24)
Adjuvant therapeutic plasma exchange in septic shock (2021) (24)
GBV‐C coinfection is negatively correlated to Fas expression and Fas‐mediated apoptosis in HIV‐1 infected patients (2008) (24)
ABT-450/r/Ombitasvir plus Dasabuvir With or Without Ribavirin in HCV Genotype 1-infected Patients Receiving Stable Opioid Substitution Treatment: Pooled Analysis of Efficacy and Safety in Phase 2 and Phase 3 Trials (2014) (24)
Long-term changes in liver elasticity in hepatitis C virus-infected patients with sustained virologic response after treatment with direct-acting antivirals (2018) (24)
Current and future treatment of hepatitis C. (2001) (23)
NK Cells in Hepatitis C: Role in Disease Susceptibility and Therapy (2012) (23)
Hepatitis B Virus Particles Activate Toll‐Like Receptor 2 Signaling Initially Upon Infection of Primary Human Hepatocytes (2020) (23)
Beyond Pegylated Interferon-Alpha: New Treatments for Hepatitis Delta. (2019) (23)
Intrahepatic long‐term persistence of parvovirus B19 and its role in chronic viral hepatitis (2009) (23)
Longer survival of liver transplant recipients with hepatitis virus coinfections (2007) (23)
Hepatitis E: An update on One Health and clinical medicine (2021) (23)
Treatment of severe, nonfulminant acute hepatitis B with lamivudine vs placebo: a prospective randomized double‐blinded multicentre trial (2014) (23)
S3-Leitlinie der Deutschen Gesellschaft für Gastroenterologie, Verdauungs- und Stoffwechselkrankheiten (DGVS) zur Prophylaxe, Diagnostik und Therapie der Hepatitis-B-Virusinfektion – (AWMF-Register-Nr. 021-11) (2021) (23)
Improved outcome of chronic hepatitis B after heart transplantation by long‐term antiviral therapy (2006) (23)
High‐resolution determination of human immune cell signatures from fine‐needle liver aspirates (2015) (23)
Simplified monitoring for hepatitis C virus treatment with glecaprevir plus pibrentasvir, a randomised non-inferiority trial. (2020) (23)
Sofosbuvir monotherapy fails to achieve HEV RNA elimination in patients with chronic hepatitis E - The HepNet SofE pilot study. (2020) (23)
Acute CMV-Colitis in a Patient with a History of Ulcerative Colitis (2003) (23)
Natural history: the importance of viral load, liver damage and HCC. (2008) (22)
BULEVIRTIDE WITH OR WITHOUT PEGIFNα FOR PATIENTS WITH COMPENSATED CHRONIC HEPATITIS DELTA: FROM CLINICAL TRIALS TO REAL LIFE STUDIES. (2022) (22)
410 FOOD INTAKE INCREASES LIVER STIFFNESS IN PATIENTS WITH CHRONIC HEPATITIS C VIRUS INFECTION (2009) (22)
Human γδ T Cell Receptor Repertoires in Peripheral Blood Remain Stable Despite Clearance of Persistent Hepatitis C Virus Infection by Direct-Acting Antiviral Drug Therapy (2018) (22)
In Situ Characterization of Intrahepatic Non-Parenchymal Cells in PSC Reveals Phenotypic Patterns Associated with Disease Severity (2014) (22)
Pegylated interferon-based treatment in patients with advanced liver disease due to chronic delta hepatitis. (2012) (22)
Angiopoietin-2 in acute liver failure* (2012) (22)
Famciclovir treatment of chronic hepatitis B in heart transplant recipients: a prospective trial. (1999) (22)
Cross‐genotype‐specific T‐cell responses in acute hepatitis E virus (HEV) infection (2016) (22)
Effect of thrombocytopenia on treatment tolerability and outcome in patients with chronic HCV infection and advanced hepatic fibrosis. (2014) (22)
Fate and Function of Hepatitis-C-Virus-Specific T-Cells during Peginterferon-α2b therapy for Acute Hepatitis C (2006) (22)
Safety and efficacy of Ombitasvir, Paritaprevir/Ritonavir and Dasabuvir with or without ribavirin in chronic hepatitis C patients receiving opioid substitution therapy: a pooled analysis across 12 clinical trials (2017) (22)
Impaired TRAIL‐dependent cytotoxicity of CD1c‐positive dendritic cells in chronic hepatitis C virus infection (2007) (21)
Combination therapy of chronic hepatitis C: an important step but not the final goal! (1998) (21)
Grazoprevir, ruzasvir, and uprifosbuvir for hepatitis C virus after NS5A treatment failure (2017) (21)
Rapid Response to Treatment of Autoimmune Hepatitis Associated with Remission at 6 and 12 Months. (2019) (21)
Polyethylene glycol–interferon: Current status in hepatitis C virus therapy (2002) (21)
Ten‐year follow‐up of a randomized controlled clinical trial in chronic hepatitis delta (2020) (21)
The number needed to treat to prevent mortality and cirrhosis‐related complications among patients with cirrhosis and HCV genotype 1 infection (2014) (21)
Structural barriers in the context of opiate substitution treatment in Germany - a survey among physicians in primary care (2013) (21)
The Third Signal Cytokine Interleukin 12 Rather Than Immune Checkpoint Inhibitors Contributes to the Functional Restoration of Hepatitis D Virus–Specific T Cells (2017) (21)
Increased seroprevalence of HAV and parvovirus B19 in children and of HEV in adults at diagnosis of autoimmune hepatitis (2018) (21)
73 A MULTICENTER ANALYSIS OF ANTIVIRAL RESPONSE AFTER ONE YEAR OF TENOFOVIR MONO-THERAPY IN HBV-MONOINFECTED PATIENTS WITH PRIOR NUCLEOS(T)IDE ANALOG EXPERIENCE (2008) (21)
Membranous Budd–Chiari syndrome in Caucasians (2010) (20)
Hepatitis E virus genome detection in commercial pork livers and pork meat products in Germany (2020) (20)
[Significance of coinfection with hepatitis G virus for chronic hepatitis C--a review of the literature]. (1998) (20)
Prevalence and genotype distribution of hepatitis delta virus among chronic hepatitis B carriers in Central Vietnam (2017) (19)
Hepatitis: Hepatitis E vaccination—is HEV 239 the breakthrough? (2011) (19)
Hepatitis Delta and HIV Infection (2012) (19)
Seroconversion to hepatitis C virus alternate reading frame protein during acute infection (2009) (19)
68Ga-PSMA-11 PET/CT Improves Tumor Detection and Impacts Management in Patients with Hepatocellular Carcinoma (2021) (19)
Letter: telaprevir triple therapy in chronic hepatitis C genotype 1 patients receiving haemodialysis (2014) (19)
Liver stiffness measurements and short-term survival after left ventricular assist device implantation: A pilot study. (2015) (19)
Automated low-flow ascites pump in a real-world setting: complications and outcomes (2018) (19)
Adenosine and IFN‐α synergistically increase IFN‐γ production of human NK cells (2009) (19)
Effectiveness and Safety of Direct-Acting Antiviral Combination Therapies for Treatment of Hepatitis C Virus in Elderly Patients: Results from the German Hepatitis C Registry (2018) (19)
Clinical significance of detectable and quantifiable HCV RNA at the end of treatment with ledipasvir/sofosbuvir in GT1 patients (2018) (18)
Safety and performance of liver biopsies in liver transplant recipients (2014) (18)
Amino Acid Substitutions within HLA-B*27-Restricted T Cell Epitopes Prevent Recognition by Hepatitis Delta Virus-Specific CD8+ T Cells (2018) (18)
Hepatitis C virus infection from the perspective of heterologous immunity. (2016) (18)
Impact of GB virus C viraemia on clinical outcome in HIV‐1‐infected patients: a 20‐year follow‐up study (2014) (18)
Hepatitis E in Deutschland – eine unterschätzte Infektionskrankheit (2014) (18)
Treatment of hepatitis C in HIV-infected patients: significant progress but not the final step. (2004) (18)
Perihepatic lymphadenopathy: a marker of response to interferon alpha in chronic hepatitis C. (1998) (18)
Real-World Safety and Effectiveness of Ombitasvir/ Paritaprevir/R with Dasabuvir and/or Ribavirin in the German Hepatitis C Registry (2016) (18)
Treatment of Naïve Patients with Chronic Hepatitis C Genotypes 2 and 3 with Pegylated Interferon Alpha and Ribavirin in a Real World Setting: Relevance for the New Era of DAA (2014) (18)
250 24 weeks of monotherapy with pegylated interferon alfa-2B in patients with acute hepatitis C (2003) (18)
Diagnosis and treatment of acute hepatitis C virus infection. (2012) (18)
Fulminant hepatic failure due to chemotherapy-induced hepatitis B reactivation: role of rituximab. (2010) (18)
Performance of Two HCV RNA Assays during Protease Inhibitor-Based Triple Therapy in Patients with Advanced Liver Fibrosis and Cirrhosis (2014) (18)
Superiority of standard interferon-alpha2b compared to pegylated interferon-alpha2b (12 kDa) in a hemodialysis patient with chronic hepatitis C? (2005) (18)
SOCS3 genetic variants and promoter hypermethylation in patients with chronic hepatitis B (2017) (17)
PEG-IFN Alpha but Not Ribavirin Alters NK Cell Phenotype and Function in Patients with Chronic Hepatitis C (2014) (17)
[Hepatitis E virus infection: a paradigm shift?]. (2010) (17)
17 KINETICS OF HBsAg DECLINE IN HBeAg+ CHRONIC HEPATITIS B PATIENTS WITH 3 YEARS OF TELBIVUDINE TREATMENT DURING THE GLOBE STUDY (2009) (17)
Evolution of Adefovir-Resistant HBV Polymerase Gene Variants after Switching to Tenofovir Disoproxil Fumarate Monotherapy (2012) (17)
Impact of ribavirin priming on viral kinetics and treatment response in chronic hepatitis C genotype 1 infection (2014) (17)
Improved immune status corresponds with long-term decline of quantitative serum hepatitis B surface antigen in HBV/HIV co-infected patients. (2012) (17)
Spontaneous clearance of chronic hepatitis C after liver transplantation: Are hepatitis C virus–specific T cell responses the clue? (2008) (17)
Interferon-free cure of chronic Hepatitis C is associated with weight gain during long-term follow-up (2017) (17)
[4 years of direct-acting antivirals (DAAs) in the German Hepatitis C-Registry (DHC-R)]. (2019) (17)
Evaluation of the COBAS(®) AmpliPrep/COBAS(®) TaqMan(®) HCV Test, v2.0 and comparison to assays used in routine clinical practice in an international multicenter clinical trial: The ExPECT study. (2015) (17)
Extra-Hepatic Replication and Infection of Hepatitis E Virus in Neuronal-Derived Cells (2016) (17)
Interferon-α for Patients with Chronic Hepatitis Delta: A Systematic Review of Randomized Clinical Trials (2012) (17)
Towards interferon-free treatment for all HCV genotypes (2015) (17)
Effects of cyclosporine on human dendritic cell subsets. (2005) (17)
Hepatitis C: therapeutic perspectives. (2001) (17)
Neuropsychiatric symptoms in hepatitis C patients resemble those of patients with autoimmune liver disease but are different from those in hepatitis B patients (2019) (16)
[Is combination therapy of chronic hepatitis C with interferon alpha and ribavirin in primary interferon nonresponders indicated?--An analysis of personal experiences and review of the literature]. (1998) (16)
Therapeutic vaccination of chronic hepatitis B patients with ABX203 (NASVAC) to prevent relapse after stopping NUCs: contrasting timing rebound between tenofovir and entecavir (2017) (16)
Monocytes transduced with lentiviral vectors expressing hepatitis C virus non-structural proteins and differentiated into dendritic cells stimulate multi-antigenic CD8(+) T cell responses. (2010) (16)
124 IMPACT OF PNPLA3 (RS738409 C>G) POLYMORPHISM ON FIBROSIS PROGRESSION AND STEATOSIS IN CHRONIC HEPATITIS C (2011) (16)
The cirrhosis risk score predicts liver fibrosis progression in patients with initially mild chronic hepatitis C (2010) (16)
Multicenter Comparison Study of both Analytical and Clinical Performance across Four Roche Hepatitis C Virus RNA Assays Utilizing Different Platforms (2017) (16)
Development of a protocol for the quantitative determination of HBeAg using the Elecsys® HBeAg immunoassay (2011) (16)
Different kinetics of HBV and HCV during haemodialysis and absence of seronegative viral hepatitis in patients with end-stage renal disease. (2011) (16)
The adverse effects of interferon‐free regimens in 149 816 chronic hepatitis C treated Egyptian patients (2018) (15)
Dulaglutide Alone and in Combination with Empagliflozin Attenuate Inflammatory Pathways and Microbiome Dysbiosis in a Non-Diabetic Mouse Model of NASH (2021) (15)
Reversal of Immunity After Clearance of Chronic HCV Infection—All Reset? (2020) (15)
1047 EARLY VERSUS DELAYED TREATMENT OF ACUTE HEPATITIS C: THE GERMAN HEP-NET ACUTE HCV-III STUDY – A RANDOMIZED CONTROLLED TRIAL (2009) (15)
HCV RNA Assay Sensitivity Impacts the Management of Patients Treated with Direct-Acting Antivirals (2015) (15)
Nitazoxanide for the treatment of chronic hepatitis C new opportunities but new challenges? (2009) (15)
Impact of direct-acting antiviral therapy on the need for liver transplantation related to hepatitis C in Germany. (2018) (15)
Estimating HCV disease burden – volume 3 (editorial) (2015) (15)
Gilbert's syndrome and antiviral therapy of hepatitis C. (2009) (15)
Risk of transfusion-transmitted hepatitis E virus infection from pool-tested platelets and plasma. (2021) (15)
GALAD Score Detects Early-Stage Hepatocellular Carcinoma in a European Cohort of Chronic Hepatitis B and C Patients (2021) (15)
Residual low HDV viraemia is associated HDV RNA relapse after PEG‐IFNa‐based antiviral treatment of hepatitis delta: Results from the HIDIT‐II study (2020) (14)
Cost of treating hepatitis C in Germany: a retrospective multicenter analysis (2014) (14)
Dynamics of CD81 expression on lymphocyte subsets during interferon‐α‐based antiviral treatment of patients with chronic hepatitis C (2006) (14)
Ombitasvir/paritaprevir/r, dasabuvir and ribavirin for cirrhotic HCV patients with thrombocytopaenia and hypoalbuminaemia (2015) (14)
Six weeks of sofosbuvir/ledipasvir (SOF/LDV) are sufficient to treat acute hepatitis C virus genotype 1 monoinfection: The HepNet Acute HCV IV Study (2016) (14)
Chronic Hepatitis E is associated with cholangitis (2019) (14)
Diagnostik, Verlauf und Therapie der Hepatitis-B-Virusinfektion - Ergebnisse einer evidenzbasierten Konsensuskonferenz der Deutschen Gesellschaft für Verdauungs- und Stoffwechselkrankheiten in Zusammenarbeit mit dem Kompetenznetz Hepatitis (2004) (14)
Safety and efficacy of the fixed-dose combination regimen of MK-3682/grazoprevir/ruzasvir in cirrhotic or non-cirrhotic patients with chronic HCV GT1 infection who previously failed a direct-acting antiviral regimen (C-SURGE) (2017) (14)
[Acute hepatitis B: is antiviral therapy indicated? Two case reports]. (2008) (14)
Prevalence of alpha-fodrin antibodies in patients with chronic hepatitis C infection and Sjögren syndrome (2009) (13)
High discontinuation rate of azathioprine in autoimmune hepatitis, independent of time of treatment initiation (2020) (13)
Long-Lasting Imprint in the Soluble Inflammatory Milieu Despite Early Treatment of Acute Symptomatic Hepatitis C (2021) (13)
Akute Hepatitis B - Ist eine antivirale Therapie indiziert? (2008) (13)
Frequent detection of HCV RNA and HCVcoreAg in stool of patients with chronic hepatitis C. (2016) (13)
Absence of Atg7 in the liver disturbed hepatic regeneration after liver injury (2020) (13)
Hepatitis E virus ORF 1 induces proliferative and functional T‐cell responses in patients with ongoing and resolved hepatitis E (2018) (13)
Safety of the 2D/3D direct-acting antiviral regimen in HCV-induced Child-Pugh A cirrhosis - A pooled analysis. (2017) (13)
Response to treatment following recently acquired hepatitis C virus infection in a multicentre collaborative cohort (2015) (13)
Dysregulated Adaptive Immunity Is an Early Event in Liver Cirrhosis Preceding Acute-on-Chronic Liver Failure (2021) (13)
Automated Nucleic Acid Isolation Methods for HDV viral Load Quantification can Lead to viral Load Underestimation (2019) (13)
The Fatty Liver Assessment in Germany (FLAG) cohort study identifies large heterogeneity in NAFLD care (2020) (13)
1213 EFFICACY AND SAFETY OF MERICITABINE (MCB) IN COMBINATION WITH PEG-IFNa-2A/RBV IN G1/4 TREATMENT NAIVE HCV PATIENTS: FINAL ANALYSIS FROM THE PROPEL STUDY (2012) (13)
Clinical course and core variability in HBV infected patients without detectable anti-HBc antibodies. (2017) (12)
Viral dominance patterns in chronic hepatitis delta determine early response to interferon alpha therapy (2018) (12)
Home-based drainage of refractory ascites by a permanent-tunneled peritoneal catheter can safely replace large-volume paracentesis. (2017) (12)
Hepatitis C Virus Infection T Cells in Chronic + Virus-Specific CD8 Impaired Effector Function of Hepatitis C (2002) (12)
Safety and efficacy of bulevirtide in combination with tenofovir disoproxil fumarate in patients with hepatitis B virus and hepatitis D virus coinfection (MYR202): a multicentre, randomised, parallel-group, open-label, phase 2 trial. (2022) (12)
Efficacy of Retreatment After Failed Direct-acting Antiviral Therapy in Patients With HCV Genotype 1-3 Infections. (2019) (12)
Efficacy and safety of bulevirtide monotherapy given at 2 mg or 10 mg dose level once daily for treatment of chronic hepatitis delta: week 48 primary end point results from a phase 3 randomized, multicenter, parallel design study (2022) (12)
366 PREVALENCE AND SEVERITY OF KIDNEY DYSFUNCTION IN PATIENTS WITH CHRONIC HEPATITIS B IN EUROPE: DATA FROM THE EUROPEAN VIRGIL COHORT (2011) (12)
Commutability and concordance of four hepatitis B virus DNA assays in an international multicenter study (2017) (12)
217 ACOUSTIC RADIATION FORCE IMAGING (ARFI) AS A NEW METHOD OF ULTRASONOGRAPHIC ELASTOGRAPHY ALLOWS ACCURATE AND FLEXIBLE ASSESSMENT OF LIVER STIFFNESS (2009) (12)
Hepatitis B virus-specific T-cell reactivity during adefovir dipivoxil (ADV) treatment: A multicentre, controlled study (2002) (12)
GS-03-Global real world evidence of sofosbuvir/velpatasvir as a simple, effective regimen for the treatment of chronic hepatitis C patients: Integrated analysis of 12 clinical practice cohorts (2019) (11)
Cost-effectiveness of Triple Therapy with Telaprevir for Chronic Hepatitis C Virus Patients in Germany (2013) (11)
61 FACTORS INFLUENCING PROGRESSION OF LIVER FIBROSIS IN PATIENTS WITH CHRONIC HEPATITIS C: RESULTS OF THE 3-YEAR T2S-918-HCV STUDY WITH HCVE1 THERAPEUTIC VACCINATION (2008) (11)
Real‐world effect of ribavirin on quality of life in HCV‐infected patients receiving interferon‐free treatment (2018) (11)
Hepatitis B infection in heart transplant recipients (2001) (11)
The Detrimental Role of Regulatory T Cells in Nonalcoholic Steatohepatitis (2021) (11)
Letter: can persisting liver stiffness indicate increased risk of hepatocellular cell carcinoma after successful anti‐HCV therapy? – authors’ reply (2016) (11)
Systemic inflammation and immune cell phenotypes are associated with neuro‐psychiatric symptoms in patients with chronic inflammatory liver diseases (2018) (11)
Eradication of Chronic HCV Infection: Improvement of Dysbiosis Only in Patients Without Liver Cirrhosis (2021) (11)
Therapie der chronischen Hepatitis C mit PEG-Interferon alpha-2b und Ribavirin: 24 Wochen Behandlung sind ausreichend bei HCV-Genotyp 2 und 3 (2003) (11)
12 Active immunization after liver transplantation for HBV related liver disease: Failure to induce HBV-specific humoral and cellular immune responses (2004) (11)
Defining Virus-specific CD8+ TCR Repertoires for Therapeutic Regeneration of T Cells against Chronic Hepatitis E. (2019) (11)
Expertenempfehlungen zur Triple-Therapie der HCV-Infektion mit Boceprevir und Telaprevir (2012) (11)
Analysis and function of delta-hepatitis virus-specific cellular immune responses (2003) (10)
Hepatitis E Virus Seroprevalence Rate in HIV-Infected Patients in Germany: A Comparison of Two Commercial Assays (2015) (10)
Alcohol and Cannabis Consumption Does Not Diminish Cure Rates in a Real-World Cohort of Chronic Hepatitis C Virus Infected Patients on Opioid Substitution Therapy—Data From the German Hepatitis C-Registry (DHC-R) (2019) (10)
Strong intrahepatic decline of hepatitis D virus RNA and antigen after 24 weeks of treatment with Myrcludex B in combinationwith Tenofovir in chronic HBV/HDV infected patients: Interim results from a multicenter, open-label phase 2b clinical trial (2018) (10)
Long‐term outcome of chronic hepatitis C virus infection in a real‐world setting: The German LOTOS study (2017) (10)
LBO-04-Efficacy and safety of sofosbuvir monotherapy in patients with chronic hepatitis E-The HepNet SofE pilot study (2019) (10)
Outcome and safety of a surveillance biopsy guided personalized immunosuppression program after liver transplantation (2021) (10)
Resistance‐associated substitutions in patients with chronic hepatitis C virus genotype 4 infection (2020) (10)
HDV infection rates in northern Vietnam (2018) (10)
DAA-Induced HCV Clearance does not Restore the Altered Cytokine and Chemokine Milieu in Patients with Chronic Hepatitis C (2016) (10)
Soluble immune markers in the different phases of chronic hepatitis B virus infection (2019) (10)
Successful direct acting antiviral (DAA) treatment of HCV/HIV-coinfected patients before and after liver transplantation (2018) (10)
Sustained HCV-RNA response and hepatitis Bs seroconversion after individualized antiviral therapy with pegylated interferon alpha plus ribavirin and active vaccination in a hepatitis C virus/hepatitis B virus-coinfected patient. (2007) (10)
[Costs of guideline-based treatment of hepatitis B patients in Germany]. (2012) (10)
Autophagy alleviates amiodarone-induced hepatotoxicity (2020) (9)
Only partial improvement in health‐related quality of life after treatment of chronic hepatitis C virus infection with direct acting antivirals in a real‐world setting—results from the German Hepatitis C‐Registry (DHC‐R) (2021) (9)
Spontaneous resolution of chronic hepatitis C virus infection after antiviral treatment and relapse. (2005) (9)
A screening assay for the identification of host cell requirements and antiviral targets for hepatitis D virus infection (2017) (9)
Real-World Clinical Practice Use of 8-Week Glecaprevir/Pibrentasvir in Treatment-Naïve Patients with Compensated Cirrhosis (2020) (9)
Quantification of polyreactive immunoglobulin G facilitates the diagnosis of autoimmune hepatitis (2021) (9)
Glecaprevir/pibrentasvir is safe and effective in hepatitis C patients with cirrhosis: Real‐world data from the German Hepatitis C‐Registry (2021) (9)
The impact of proton pump inhibitors on the intestinal microbiota in chronic hepatitis C patients (2018) (9)
Autoimmune hepatitis and overlap syndromes (2002) (9)
Treatment of chronic hepatitis B and the implications of viral resistance to therapy (2008) (9)
Letter: a 5‐year long‐term follow‐up study after DAA treatment confirms a reduced HCC risk in a central European cohort of HCV patients with liver cirrhosis (2020) (9)
35 HEPATITIS E AS A ZOONOSIS AND THE RELEVANCE FOR LIVER TRANSPLANT RECIPIENTS (2009) (9)
Risk factors and seroprevalence of hepatitis E evaluated in frozen‐serum samples (2002‐2003) of pregnant women compared with female blood donors in a Southern region of Brazil (2018) (9)
Autoimmune hepatitis induction can occur in the liver (2019) (9)
Flares during long‐term entecavir therapy in chronic hepatitis B (2016) (9)
Intranuclear inclusions in hepatocellular carcinoma contain autophagy‐associated proteins and correlate with prolonged survival (2019) (9)
[Diagnosis, progression and therapy of hepatitis-B-virus infection--results of an evidenced based consensus conference of the German Society for Alimentary Metabolic Disorders and and in cooperation with the Hepatitis Competence Network]. (2004) (9)
Pilot Study Using Machine Learning to Identify Immune Profiles for the Prediction of Early Virological Relapse After Stopping Nucleos(t)ide Analogues in HBeAg‐Negative CHB (2020) (9)
NAFLD-Associated Comorbidities in Advanced Stage HCC Do Not Alter the Safety and Efficacy of Yttrium-90 Radioembolization (2019) (9)
Hepatitis E Virus (HEV)-Specific T Cell Receptor Cross-Recognition: Implications for Immunotherapy (2019) (8)
Acute hepatitis B: is antiviral therapy necessary? Two illustrative case reports (2008) (8)
Modulation of HCV reinfection after orthotopic liver transplantation by fibroblast growth factor-2 and other non-interferon mediators (2015) (8)
Economic evaluation of early monotherapy versus delayed monotherapy or combination therapy in patients with acute hepatitis C in Germany (2010) (8)
Disclosure behaviour and experienced reactions in patients with HIV versus chronic viral hepatitis or diabetes mellitus in Germany (2013) (8)
Hepatitis C in 2012: On the fast track towards IFN-free therapy for hepatitis C? (2013) (8)
Altered effector functions of NK cells in chronic hepatitis C are associated with IFNL3 polymorphism (2015) (8)
[Expert recommendations: Hepatitis C and transplantation]. (2016) (8)
Renal function during treatment with adefovir plus peginterferon alfa‐2a vs either drug alone in hepatitis B/D co‐infection (2012) (8)
and weight-based ribavirin in patients with genotype (2011) (8)
BH3-only protein expression determines hepatocellular carcinoma response to sorafenib-based treatment (2021) (8)
Early versus delayed treatment of acute hepatitis C: Final results of the randomized controlled German HEP-NET acute HCV-III study (2012) (8)
[German guidelines on diagnosis and therapy of hepatitis B]. (2007) (8)
Exacerbation of hepatitis E virus infection during anti-TNFα treatment. (2017) (8)
Comprehensive Evaluation of Hepatitis E Serology and Molecular Testing in a Large Cohort (2020) (8)
[Problems in treating patients with chronic HCV infection due to the COVID-19 pandemic and during the lockdown phase in Germany]. (2020) (8)
Clinical Impact of Liver Biopsies in Liver Transplant Recipients. (2017) (8)
Aktuelle Empfehlung der DGVS und des bng zur Therapie der chronischen Hepatitis C (2014) (8)
Clinical and biochemical endpoints and predictors of response to plasma exchange in septic shock: results from a randomized controlled trial (2022) (8)
Characterization of two types of intranuclear hepatocellular inclusions in NAFLD (2020) (8)
Review article: HCV ? STAT-C era of therapy (2010) (8)
The suppressive effect that myriocin has on hepatitis C virus RNA replication is independent of inhibition of serine palmitoyl transferase. (2008) (7)
HBV‐specific T‐cell responses in healthy seronegative sexual partners of patients with chronic HBV infection (2009) (7)
Treatment duration in acute hepatitis C: The issue is not solved yet (2006) (7)
745 Stopping Long-Term Nucleos(t)ide Analogue Therapy Before Hbsag Loss or Sero-Conversion in Hbeag Negative Chb Patients: Experience From Four Referral Centers in Germany (2011) (7)
Absence of chronic hepatitis E in a German cohort of common variable immunodeficiency patients (2012) (7)
Symptoms of anxiety and depression are frequent in patients with acute hepatitis C and are not associated with disease severity (2015) (7)
[Knowledge and management of hepatitis B virus infected patients in Germany]. (2012) (7)
294 Safety and antiviral effect of BILN 2061, a novel HCV serine protease inhibitor, after oral treatment over 2 days in patients with chronic hepatitis C, genotype 1, and liver cirrhosis (2003) (7)
Safety and efficacy of tenofovir alafenamide in liver transplant recipients: A single center experience (2020) (7)
Treatment strategies for patients with decompensated liver cirrhosis due to hepatitis C virus infection eligible for liver transplantation: real-life data from five German transplant centers (2019) (7)
Multicentric performance analysis of HCV quantification assays and its potential relevance for HCV treatment (2015) (7)
The burden of hepatitis D - defogging the epidemiological horizon. (2020) (7)
Updated epidemiology of hepatitis C virus infections and implications for hepatitis C virus elimination in Germany (2022) (7)
Quantitation of large, middle and small hepatitis B surface proteins in HBeAg‐positive patients treated with peginterferon alfa‐2a (2019) (7)
Treatment of hepatitis C virus-associated inflammatory polyneuropathy with pegylated interferon-alpha and ribavirin. (2007) (7)
All oral fixed-dose combination Sofosbuvir/Ledipasvir with or without Ribavirin for 12 or 24 weeks in treatment-naive genotype 1 HCV-infected patients: the phase 3 ION-1 study (2014) (7)
How to interpret borderline HCV antibody test results: a comparative study investigating four different anti-HCV assays. (2014) (7)
Incorporation of primary patient‐derived glycoproteins into authentic infectious hepatitis C virus particles (2014) (7)
Treatment of acute hepatitis C-how to explain the differences? (2006) (7)
1403 SIGNIFICANT IMPROVEMENT OF COMPLETE EVR IN HCVAC PHASE II CLINICAL TRIAL WHEN ADDING TG4040 THERAPEUTIC VACCINE TO PEGIFNα2A AND RIBAVIRIN (2012) (7)
479 Significance of HDV-RNA and HBsAg levels in delta hepatitis: First data of the Hep-Net/international HDV intervention trial (2006) (7)
Anti-CD20 Therapy Alters the Protein Signature in Experimental Murine AIH, but Not Exclusively towards Regeneration (2021) (7)
Hippo Pathway Counter-Regulates Innate Immunity in Hepatitis B Virus Infection (2021) (7)
Development and performance of prototype serologic and molecular tests for hepatitis delta infection (2018) (7)
Prospects and Challenges for T Cell-Based Therapies of HCC (2021) (7)
1012 TELBIVUDINE-INDUCED HBEAG SEROCONVERSION IN CHRONIC HEPATITIS B (CHB) IS DURABLE DURING 2 YEARS OFF-TREATMENT FOLLOW-UP (2010) (7)
Mericitabine and Either Boceprevir or Telaprevir in Combination with Peginterferon Alfa-2a plus Ribavirin for Patients with Chronic Hepatitis C Genotype 1 Infection and Prior Null Response: The Randomized DYNAMO 1 and DYNAMO 2 Studies (2016) (7)
Evaluation of Point Shear Wave Elastography Using Acoustic Radiation Force Impulse Imaging for Longitudinal Fibrosis Assessment in Patients with HBeAg-Negative HBV Infection (2019) (6)
Role of immunohistochemistry for hepatitis D and hepatitis B virus in hepatitis delta (2014) (6)
Different kinetics of liver stiffness using shear wave elastography in patients with chronic hepatitis C infection treated with interferon-free regimens (2019) (6)
Risk of infections during interferon‐based treatment in patients with chronic hepatitis C virus infection and advanced hepatic fibrosis (2015) (6)
Simultaneous mitral valve replacement and liver transplantation. (2011) (6)
Impact on follow‐up strategies in patients with primary sclerosing cholangitis (2022) (6)
46 LONG-TERM FOLLOW-UP AFTER PEG-IFNa2a-BASED THERAPY OF CHRONIC HEPATITIS DELTA (2013) (6)
Does the presence of adefovir-resistant variants lead to failure of tenofovir monotherapy? (2008) (6)
HBcrAg Levels Are Associated With Virological Response to Treatment With Interferon in Patients With Hepatitis Delta (2021) (6)
Splenectomy Prior to Experimental Induction of Autoimmune Hepatitis Promotes More Severe Hepatic Inflammation, Production of IL-17 and Apoptosis (2021) (6)
806 MANAGEMENT AND OUTCOMES OF ANEMIA IN THE INTERNATIONAL TELAPREVIR EARLY ACCESS PROGRAM, FOR PATIENTS WITH HEPATITIS C GENOTYPE 1 INFECTION (2013) (6)
Ledipasvir/Sofosbuvir Treatment for 8 Weeks in Treatment-Naïve HCV Genotype 1 Infected Patients under Real Life Conditions: Data from the German Hepatitis C-Registry (DHC-R) (2016) (6)
The role of different EASL-papers: Clinical practice guidelines vs. position papers vs. conference summaries (2010) (6)
Treatment Extension of Pegylated Interferon Alpha and Ribavirin Does Not Improve SVR in Patients with Genotypes 2/3 without Rapid Virological Response (OPTEX Trial): A Prospective, Randomized, Two-Arm, Multicentre Phase IV Clinical Trial (2015) (6)
Apolipoprotein E polymorphisms and their protective effect on hepatitis E virus replication (2016) (6)
Pneumococcal meningitis during antiviral treatment with interferon and ribavirin in a splenectomized patient with chronic hepatitis C - do not miss vaccination before starting therapy. (2008) (6)
Impaired effector function of HCV-specific CD8+ T cells in chronic hepatitis C virus infection (2001) (6)
Final Results of the Telaprevir Access Program: FibroScan Values Predict Safety and Efficacy in Hepatitis C Patients with Advanced Fibrosis or Cirrhosis (2015) (6)
Treatment of acute hepatitis C infection with interferon-alfa 2b monotherapy prevents development of chronic HCV infection (2001) (6)
SNPs Within the MTOR Gene Are Associated With an Increased Risk of Developing De Novo Diabetes Mellitus Following the Administration of Everolimus in Liver Transplant Recipients. (2019) (6)
Intra-host analysis of hepaciviral glycoprotein evolution reveals signatures associated with viral persistence and clearance (2022) (6)
No increased incidence for GB‐virus C infection in a cohort of HIV‐positive lymphoma patients (2011) (6)
Hepatitis als Reisekrankheit (2004) (6)
Kompetenznetz Hepatitis (Hep-Net) (2004) (6)
[Current recommendations for the treatment of chronic hepatitis C]. (2014) (6)
New Treatments for Chronic Hepatitis B Virus/Hepatitis D Virus Infection. (2021) (6)
Dronedarone, amiodarone and other antiarrhythmic drugs, and acute liver injuries: a case-referent study. (2018) (6)
[Standard treatment of chronic hepatitis B]. (2004) (6)
Deutsches Hepatitis C-Register (DHC-R) – eine Zwischenbilanz 4 Jahre nach Zulassung direkt antiviraler Substanzen (DAAs) (2019) (6)
48 EARLY VERSUS DELAYED TREATMENT OF ACUTE HEPATITIS C: FINAL RESULTS OF THE RANDOMIZED CONTROLLED GERMAN HEP-NET ACUTE HCV-III STUDY (2012) (6)
322 SHOULD ALL PATIENTS WITH AUTOIMMUNE HEPATITIS BE SCREENED FOR HEV-INFECTION? (2010) (6)
Effects of therapeutic plasma exchange on the endothelial glycocalyx in septic shock (2021) (6)
1044 EVALUATION OF A NOVEL ULTRASOUND METHOD FOR THE DETECTION OF LIVER FIBROSIS – PROSPECTIVE COMPARISON WITH TRANSIENT DYNAMIC ELASTOGRAPHY AND HISTOLOGY (2010) (6)
Imprint of unconventional T‐cell response in acute hepatitis C persists despite successful early antiviral treatment (2021) (6)
Histological and serological features of acute liver injury after SARS-CoV-2 vaccination (2022) (6)
A Rapid Point-of-Care Test for the Serodiagnosis of Hepatitis Delta Virus Infection (2021) (5)
Case Report: Convalescent Plasma Therapy Induced Anti-SARS-CoV-2 T Cell Expansion, NK Cell Maturation and Virus Clearance in a B Cell Deficient Patient After CD19 CAR T Cell Therapy (2021) (5)
Comprehensive phenotyping of regulatory T cells after liver transplantation (2015) (5)
Hepatitis C virus-specific T cell responses against conserved regions in recovered patients. (2009) (5)
Hepatitis C RNA assay differences in results: Potential implications for shortened therapy and determination of Sustained Virologic Response (2016) (5)
Acute hepatitis C virus infection: to treat or not to treat? (2004) (5)
Treatment of hepatitis Delta (2013) (5)
Interferon-based treatment of chronic hepatitis D. (2022) (5)
Sustained Virologic Response Rate of 96% in HCV Genotype 1a-Infected Patients Treated With Ombitasvir/Paritaprevir/r and Dasabuvir With Ribavirin: 2048 (2015) (5)
Hepatitis E In Transplant Recipients: Why Is This Not A Problem In Japan? (2015) (5)
Efficacy and Safety of Ombitasvir/Paritaprevir/Ritonavir and Dasabuvir With or Without Ribavirin in Patients With Chronic Hepatitis C Virus Genotype 1 Infection Receiving Opioid Substitution Therapy: A Post Hoc Analysis of 12 Clinical Trials (2018) (5)
99.7% Sustained Virologic Response Rate in 369 HCV Genotype 1b-Infected Patients Treated With Label-Recommended Regimen of Ombitasvir/Paritaprevir/r and Dasabuvir With or Without Ribavirin: 2016 (2015) (5)
P0559 : Evaluation of large, middle and small hepatitis B surface (HBS) proteins in HBeAg positive patients (2015) (5)
Stomach reduction or gastric bypass as risk factor for treatment failure after DAA therapy for hepatitis C? (2017) (5)
Republished paper: Managing HBV in patients with impaired immunity (2010) (5)
67 Hepatitis C viral kinetics in chronically infected patients treated with the serine protease inhibitor BILN 2061 (2004) (5)
THU-188-Retreatment with sofosbuvir/velpatasvir/voxilaprevir in patients with chronic hepatitis C virus infection and prior DAA failure: An analysis from the German hepatitis C registry (DHC-R) (2019) (5)
333 KINETICS OF HCV CORE ANTIGEN DURING ANTIVIRAL TREATMENT OF ACUTE AND CHRONIC HEPATITIS C AS DETERMINED BY A NOVEL CHEMILUMINESCENT MICROPARTICLE IMMUNOASSAY (2009) (5)
The hepatitis E virus: a likely cause of extrahepatic diseases! (2016) (5)
Effectiveness of Peginterferon Alfa-2a Therapy in HBeAg-Positive and HBeAg-Negative Patients with Chronic Hepatitis B: Final Results 3 Years Post-Treatment of the Prospective, Global, Observational S-Collate Study (2016) (5)
Article Commentary: Is There a Need for Liver Disease Monitoring in HIV Patients in Africa? (2011) (5)
T‐cell driven allergic cutaneous reaction complicating treatment of hepatitis delta virus infection with bulevirtide (2022) (5)
[27] DIFFERENTIAL CYTOKINE PATTERN OF HDV-SPECIFIC CELLULAR IMMUNE RESPONSES DISTINGUISHES TREATMENT RESPONDER AND NONRESPONDER TO PEG-IFNa-2a TREATMENT: RESULTS FROM THE HEP-NET/INTERNATIONAL HIDIT-1 STUDY (2007) (5)
Role of soluble inflammatory mediators and different immune cell populations in early control of symptomatic acute hepatitis C virus infection (2018) (5)
Risk of recurrent hepatic encephalopathy in patients with liver cirrhosis: a German registry study (2020) (5)
P0808 : Improvement in liver function and non-invasive estimates of liver fibrosis 48 weeks after treatment with ombitasvir/paritaprevir/R, dasabuvir and ribavirin in HCV genotype 1 patients with cirrhosis (2015) (5)
Rituximab leads to reactivation of hepatitis B in individuals with resolved infection (2009) (5)
929 EVALUATION OF SAFETY AND TOLERABILITY OF TENOFOVIR DF (TDF) LONG TERM MONOTHERAPY IN NUCLEOS(T)IDE ANALOGUE EXPERIENCED PATIENTS WITH HBV MONOINFECTION (2009) (5)
Elevated fractional donor‐derived cell‐free DNA during subclinical graft injury after liver transplantation (2022) (5)
Peginterferon Alfa-2a (40 kD) Stopping Rules in Chronic Hepatitis B: A Systematic Review and Meta-Analysis of Individual Participant Data (2019) (5)
793 REAL-LIFE DATA OF TELAPREVIR-BASED TRIPLE-THERAPY IN PATIENTS WITH CHRONIC HEPATITIS C GT1 IN GERMANY – AN INTERIM ANALYSIS (2013) (4)
Intravenous ketamine is a risk factor for jaundice in Covid-19 patients (2021) (4)
[226] LONG-TERM TREATMENT WITH PEG-IFN-ALFAb REDUCES HEPATOCELLULAR INCIDENCE AND PREVENTS CLINICAL COMPLICATIONS IN HEPATITIS C CIRRHOSIS - AN INTERIM ANALYSIS OF A MULTICENTER TRIAL (2007) (4)
Weight Gain after Interferon-Free Treatment of Chronic Hepatitis C—Results from the German Hepatitis C-Registry (DHC-R) (2019) (4)
770 STOPPING LONG-TERM NUCLEOS(T)IDE ANALOGUE THERAPY BEFORE HBsAg LOSS IN HBeAg NEGATIVE CHB PATIENTS: FOLLOW-UP OF LONG TERM RESPONDERS (2013) (4)
Natural Killer Cells Regulate the Maturation of Liver Sinusoidal Endothelial Cells Thereby Promoting Intrahepatic T‐Cell Responses in a Mouse Model (2021) (4)
Clinical and Virological Aspects of HBV Reactivation: A Focus on Acute Liver Failure (2019) (4)
Increase of α-dicarbonyls in liver and receptor for advanced glycation end products on immune cells are linked to nonalcoholic fatty liver disease and liver cancer (2021) (4)
P0661 : Prediction of HBeAg seroconversion in HBeAg-positive chronic hepatitis B patients treated with entecavir using ALT and platelet count: Results from a large european multi-center study (2015) (4)
Telaprevir‐based triple‐therapy in patients with chronic hepatitis C in Germany: a 12‐week interim analysis of real‐life data (2012) (4)
Hepatitis C virus: Current steps toward elimination in Germany and barriers to reaching the 2030 goal (2021) (4)
Poor clinical and virological outcome of nucleos(t)ide analogue monotherapy in HBV/HDV co-infected patients (2021) (4)
Long-term follow-up after IFN-free therapy of advanced HCV-associated liver cirrhosis: continued improvement of liver function parameters – Results from the German Hepatitis C-Registry (DHC-R) (2017) (4)
544 A EUROPEAN FIELD STUDY OF THE EFFICACY AND SAFETY OF TENOFOVIR DISOPROXIL FUMARATE (TDF) AS MONOTHERAPY IN PATIENTS WITH PRIOR FAILURE TO OTHER NUCLEOSIDE/NUCLEOTIDE ANALOGUES (2012) (4)
Safety of Direct-Acting Antivirals-Based Therapy for the Treatment of Patients with Chronic Hepatitis C Virus Infection and Cirrhosis: Results from an International Multicenter Cohort Study (2016) (4)
Immunological, virological and clinical long-term follow-up after interferon therapy of acute hepatitis C infection (2003) (4)
Treatment-failure to direct antiviral HCV regimens in real world: frequency, patient characteristics and rescue therapy – data from the German hepatitis C registry (DHC-R) (2020) (4)
Early on-treatment HDV-RNA kinetics are not predictive for long-term response to a PEG-IFNa therapy of hepatitis delta (2015) (4)
Safety and efficacy of prophylactic and therapeutic vaccine based on live-attenuated Listeria monocytogenes in hepatobiliary cancers (2022) (4)
1255 CHRONIC HEPATITIS E IN IMMUNOSUPPRESSED PATIENTS BEYOND LIVER- AND KIDNEY TRANSPLANTATION (2011) (4)
932 FACTORS ASSOCIATED WITH HEPATOCELLULAR CARCINOMA IN CHRONIC HEPATITIS C PATIENTS WITH ADVANCED LIVER FIBROSIS (2012) (4)
Hepatitis B infection in heart transplant patients. (2001) (4)
Farnesoid X receptor agonist tropifexor attenuates cholestasis in a randomised trial in patients with primary biliary cholangitis (2022) (4)
48 ENHANCEMENT OF HEPATITIS C VIRUS ENTRY BY STEROIDS (2009) (4)
[Hepatitis as a travel disease]. (2004) (4)
Hepatitis E virus is highly resistant to alcohol-based disinfectants. (2022) (4)
Weight Gain after IFN-Free Cure of Chronic Hepatitis C: A Potential Concern? (2016) (4)
Gradual increase in platelets following sustained virological response among patients with HCV-induced advanced hepatic fibrosis (2013) (4)
Liver transplantation: A new risk factor for intestinal intussusceptions. (2011) (4)
[Treatment of chronic hepatitis C with PEG-interferon alpha-2b and ribavirin: 24 weeks of therapy are sufficient for HCV genotype 2 and 3]. (2003) (4)
144 REDUCED DOSE AND DURATION OF PEGINTERFERON ALFA-2B + WEIGHT-BASED RIBAVIRIN IN EUROPEAN AND ASIAN GENOTYPE 2 AND 3 CHRONIC HEPATITIS C PATIENTS (REDD 2/3 TRIAL) (2009) (4)
Dose-dependent durability of hepatitis B surface antigen reductions following administration of a single dose of VIR-3434, a novel neutralizing vaccinal monoclonal antibody (2022) (4)
1028 RENAL SAFETY AND ANTIVIRAL EFFICACY OF TENOFOVIR DISOPROXIL FUMARATE (TDF) MONOTHERAPY IN NUCLEOS(T)IDE ANALOGUE REFRACTORY PATIENTS WITH HEPATITIS B VIRUS (HBV) MONO-INFECTION (2010) (4)
36 Induction of hepatitis C virus specific T cells by needle stick injury in the absence of HCV-viremia (2003) (4)
Of guinea pigs and men--an unusual case of jaundice. (2010) (4)
DSM-TACE of HCC: Evaluation of Tumor Response in Patients Ineligible for Other Systemic or Loco-Regional Therapies (2020) (4)
Gender differences in patient receiving liver transplantation for viral hepatitis. (2012) (4)
Irreversible impact of chronic hepatitis C virus infection on human natural killer cell diversity (2018) (4)
617 E1 therapeutic vaccination in patients with chronic HCV genotype 1 infection: Results of a 15-month, placebo-controlled trial (2006) (4)
Predictors of response to intra-arterial vasodilatory therapy of non-occlusive mesenteric ischemia in patients with severe shock: results from a prospective observational study (2022) (4)
Predominance of HBV Genotype B and HDV Genotype 1 in Vietnamese Patients with Chronic Hepatitis (2021) (4)
Sofosbuvir, velpatasvir, and voxilaprevir for patients with failure of previous direct-acting antiviral therapy for chronic hepatitis C: Results from the German Hepatitis C-Registry (DHC-R) (2020) (4)
Upregulation of SMYD3 and SMYD3 VNTR 3/3 polymorphism increase the risk of hepatocellular carcinoma (2020) (3)
Depressionen und Lebererkrankungen: Die Rolle von Mikrobiom und Inflammation (2019) (3)
987 HIGH PREVALENCE OF HEPATITIS MARKER IN IMMIGRANT POPULATIONS: A PROSPECTIVE MULTICENTER SCREENING APPROACH IN A REAL WORLD SETTING (2012) (3)
Hepatitis B virus particles activate toll-like receptor 2 signaling initial upon infection of primary human hepatocytes (2019) (3)
Impact of HBV coinfection on hepatitis C virus infection: analysis of 3054 anti HCV-positive patients (2001) (3)
Auswirkungen einer SARS-CoV-2-Infektion auf Symptomatik und Therapie chronisch-entzündlicher Darmerkrankungen (2021) (3)
Versorgungsprobleme von Patienten mit chronischer Hepatitis C während der COVID-19-Pandemie und der Lockdown-Verordnungen (2020) (3)
Significant compartment‐specific impact of different RNA extraction methods and PCR assays on the sensitivity of hepatitis E virus detection (2021) (3)
Current Management of HBV/HDV Coinfection and Future Perspectives (2015) (3)
Wie lässt sich die Eliminierung von Hepatitis B, C und D in Deutschland messen? Ergebnisse eines interdisziplinären Arbeitstreffens (2020) (3)
Liver stiffness across different chronic liver disease under therapy with statin in a real life cohort. (2020) (3)
504 IMPROVEMENT OF INTERFERON-BASED THERAPY SUBSTANTIALLY REDUCED THE NUMBER NEEDED TO TREAT TO PREVENT HCC AMONG HCV GENOTYPE 1 INFECTED CIRRHOTICS (2013) (3)
Home‐based, tunnelled peritoneal drainage system as an alternative treatment option for patients with refractory ascites (2022) (3)
Six weeks of Sofosbuvir/Ledipasvir treatment of acute hepatitis C Virus genotype 1 monoinfection: Final results of the German HepNet Acute HCV IV Study (2016) (3)
855 A CLINICAL TRIAL EVALUATING LOW HCVRNA VIREMIA IN PATIENTS TREATED WITH TRIPLE THERAPY REGIMENS: IMPLICATIONS FOR PATIENT MANAGEMENT USING DIFFERENT ASSAYS IN CLINICAL PRACTICE (2013) (3)
Reaching the Unreachable: Strategies for HCV Eradication in Patients With Refractory Opioid Addiction—A Real-world Experience (2021) (3)
Potential viral triggers for pediatric and adult autoimmune hepatitis (2017) (3)
The impact of hepatitis B surface antigen on natural killer cells in patients with chronic hepatitis B virus infection (2021) (3)
Pegylated interferons in combination with ribavirin for the treatment of chronic hepatitis C (2003) (3)
P1206 ITPA GENE VARIANTS AND ANEMIA DURING TELAPREVIR/PEGINTERFERON/RIBAVIRIN COMBINATION THERAPY IN PATIENTS WITH CHRONIC HEPATITIS C INFECTION (2014) (3)
PS-184-Real-world effectiveness and safety of glecaprevir/pibrentasvir in adults with chronic hepatitis C virus infection: A meta-analysis (2019) (3)
CASE REPORT: A Rare Manifestation of Behçet's Syndrome: Immunological Correlates and Successful Treatment of an Esophageal Ulcer (2003) (3)
Noninvasive Models for Predicting Liver Fibrosis in Individuals with Hepatitis D Virus/Hepatitis B Virus Coinfection in the Brazilian Amazon Region. (2020) (3)
[605] THERAPEUTIC PEPTIDE VACCINATION AGAINST CHRONIC HEPATITIS C VIRUS INFECTION (2007) (3)
IgG, a novel predictor for acute-on-chronic liver failure and survival in patients with decompensated cirrhosis? (2021) (3)
From volcano clouds to iLivers: EASL growing in times of change. (2011) (3)
Sustained Virological Response Improves Overall Survival in Chronic Hepatitis C Patients with Advanced Fibrosis (2011) (3)
Performance and Value of IFN-Lambda3 and IFN-Lambda4 Genotyping in Patients with Chronic Hepatitis C (CHC) Genotype 2/3 in a Real World Setting (2015) (3)
Rral-life data of telaprevir-based triple-therapy in patients with chronic hepatitis C GT1 in Germany – an interim analysis (2013) (3)
A transient early HBV‐DNA increase during PEG‐IFNα therapy of hepatitis D indicates loss of infected cells and is associated with HDV‐RNA and HBsAg reduction (2020) (3)
Benefit of Treatment Individualization in Patients with Chronic Hepatitis C Receiving Peginterferon Alfa-2a and Ribavirin in a Large Noninterventional Cohort Study (2015) (3)
928 EFFECTIVENESS OF TENOFOVIR DF (TDF) MONOTHERAPY IN PATIENTS WITH PRIOR EXPERIENCE TO NUCLEOSIDE/NUCLEOTIDE ANALOGUES BY DIFFERENT PATTERN OF PRE-EXISTING MUTATIONS (2009) (3)
Hepatitis C new drugs (2010) (3)
Long-lasting tumour response to sorafenib therapy in advanced hepatocellular carcinoma. (2014) (3)
Safety and Efficacy of IFN- Free Antiviral Therapies in Advanced HCV- Associated Liver Cirrhosis: Results from the German Hepatitis C-Registry (DHC-R) (2016) (3)
[Hepatitis (Hep-Net) competence network]. (2004) (3)
Real-World Medical Costs of Antiviral Therapy Among Patients With Chronic Hcv Infection and Advanced Hepatic Fibrosis. (2015) (3)
Hepatitis C virus living off the fat of the land (2007) (3)
O163 TURQUOISE-II: SVR12 RATES OF 92–96% IN 380 HEPATITIS C VIRUS GENOTYPE 1-INFECTED ADULTS WITH COMPENSATED CIRRHOSIS TREATED WITH ABT-450/R/ABT-267 AND ABT-333 PLUS RIBAVIRIN (3D+RBV) (2014) (3)
HBV‐RNA Co‐amplification May Influence HBV DNA Viral Load Determination (2020) (3)
1020 SAFETY AND EFFICACY OF ENTECAVIR AND TENOFOVIR COMBINATION-THERAPY IN HEPATITIS B PATIENTS WITH PREVIOUS TREATMENT FAILURES. AN INTERNATIONAL MULTICENTER COHORT STUDY (2010) (3)
Scaling up HCV-DAA treatment in patients on opioid substitution therapy (OST) – does alcohol and cannabis diminish cure rates? Data from the German Hepatitis C-Registry (DHC-R) (2018) (3)
Reverse Inflammaging: Long-term effects of HCV cure on biological age (2022) (3)
Virushepatitis und Schwangerschaft (1974) (3)
1014 Improvement in Liver Function and Non-Invasive Estimates of Liver Fibrosis 48 Weeks After Treatment With Ombitasvir/Paritaprevir/R, Dasabuvir and Ribavirin in HCV Genotype 1 Patients With Cirrhosis (2015) (3)
1159 SERUM ZINC BUT NOT SERUM VITAMIN D LEVELS ARE ASSOCIATED WITH DISEASE SEVERITY AND TREATMENT RESPONSE IN CHRONIC HEPATITIS C VIRUS INFECTION (2011) (3)
No association between IFNL3 (IL28B) genotype and response to peginterferon alfa-2a in HBeAg-positive or -negative chronic hepatitis B (2018) (3)
160 Prove2 Study: Treatment of Chronic Hepatitis C with Telaprevir (TVR)in Combination with Peginterferon-Alfa-2a with or Without Ribavirin, Interim Analysis Results (2008) (3)
Real‐world medical costs of antiviral therapy among patients with chronic HCV infection and advanced hepatic fibrosis (2016) (3)
Präsidentenposter: Early versus delayed treatment of acute hepatitis C: The German HEP-NET acute HCV-III study – a randomized controlled trial (2009) (2)
Influence of PML, RASSF6 and NLRP12 on growth and recurrence of human hepatocellular carcinoma (2020) (2)
Inflammatory patterns in plasma associate with hepatocellular carcinoma development in cured hepatitis C cirrhotic patients (2020) (2)
Interferon-free cure of hepatitis C virus infection does alter the soluble inflammatory milieu which could affect hepatocellular carcinoma surveillance by CD8+ T cells in patients with liver cirrhosis (2017) (2)
P0877 : HCVRNA levels assessed at early stages of sofosbuvir/ribavirin dual therapy identify relapse patients (2015) (2)
Clinical evaluation of a novel Fast-track diagnostics multiplex real-time PCR assay for detection and quantification of Hepatitis E virus (2015) (2)
Elevated liver enzymes predict morbidity and mortality despite antiviral cure in patients with chronic hepatitis C: Data from the German Hepatitis C‐Registry (2022) (2)
P0735 : Assessment of baseline viral load cut-off for shortened ledipasvir/sofosbuvir therapy by widely used HCVRNA assays (2015) (2)
Diversity of clinical presentation and virological characteristics of hepatitis delta in different regions world-wide: results of the Hepatitis Delta International network (2017) (2)
HCV-RNA kinetics on-treatment do not predict sustained virologic response in HCV genotype 3 patients receiving sofosbuvir and ribavirin (2016) (2)
Pegylated interferon-alfa–2a plus adefovir combination therapy is superior to pegylated interferon-alfa–2a alone or adefovir monotherapy in reducing HBsAg levels in HDV-coinfected patients with low HBV viremia (2007) (2)
Long-term changes of liver elasticity in HVC-infected patients with SVR after treatment with direct-acting antivirals (2018) (2)
857 TRIPLE THERAPY FOR HEPATITIS C VIRUS (HCV) INFECTION IN PATIENTS WITH COMPENSATED LIVER CIRRHOSIS: LESSONS LEARNED FROM THE FIRST REAL-WORLD EXPERIENCE (2013) (2)
Acute hepatitis C infection: Can immunology teach us the right way to treat? (2004) (2)
Promyelocytic leukemia protein deficiency leads to spontaneous formation of liver tumors in hepatitis C virus transgenic mice (2019) (2)
Telemonitoring-Supported Exercise Training in Employees With Metabolic Syndrome Improves Liver Inflammation and Fibrosis (2021) (2)
Interferon-free therapy of chronic hepatitis C does not change the short-term risk for de novo hepatocellular carcinomas in patients with liver cirrhosis (2017) (2)
Safety and Efficacy of 10 mg Myrcludex B/IFNa Combination Therapy in Patients with Chronic HBV/HDV Co-Infection (2020) (2)
Reduced humoral but stable cellular SARS-CoV-2-specific immunity in liver transplant recipients in the first year after COVID-19 (2022) (2)
Efficacy and safety of tenofovir disoproxil fumarate (TDF) monotherapy in a European multicenter cohort of nucleos(t)ide experienced patients with chronic hepatitis B virus (HBV)-infection (2010) (2)
382 PROLONGED INTRAHEPATIC HEPATITIS DELTA ANTIGEN PERSISTENCE AFTER LIVER TRANSPLANTATION (LTX) DESPITE RAPID EARLY SERUM HDVRNA DECLINE AFTER LTX (2011) (2)
Impact of the COVID-19 pandemic on patients with liver cirrhosis—the experience of a tertiary center in Germany (2021) (2)
PS-178-Simplified monitoring for hepatitis C virus treatment with glecaprevir plus pibrentasvir: the SMART-C study (2019) (2)
Increasing Number of Individuals Receiving Hepatitis B nucleos(t)ide Analogs Therapy in Germany, 2008–2019 (2021) (2)
Final analysis of the international observational S-Collate study of peginterferon alfa-2a in patients with chronic hepatitis B (2020) (2)
No Impact of Insulin Resistance on Antiviral Efficacy of Telaprevir-based regimen in HCV Genotype 1 Treatment-Naive Patients: Subanalysis of C208 Study (2011) (2)
P0754 : Clinical significance of drug-drug interactions during therapy with novel daas against HCV (2015) (2)
364 HBsAg SERUM LEVELS ARE ASSOCIATED WITH THE PHASE OF HBV-INFECTION (2009) (2)
Effectiveness and Safety of DAA Combination Therapies for Treatment of HCV in Elderly Patients (>70 Yrs): Results from the German Hepatitis C-Registry (2016) (2)
Can epoetin alfa maintain ribavirin doses in patients with hepatitis C virus on combination therapy? (2004) (2)
Soluble inflammatory mediators identify HCV patients who may be cured with four weeks of antiviral treatment (2022) (2)
1232 INCREASED HEV SEROPREVALENCE IN PATIENTS WITH AUTOIMMUNE HEPATITIS (2013) (2)
P209: Near full‐length hepatitis E virus genome sequencing analysis in a chronically infected patient following ribavirin treatment failure (2015) (2)
Treatment of hepatitis C genotype 1 patients with severe fibrosis or compensated cirrhosis: The german telaprevir early access program (2013) (2)
Delayed early HCV RNA response during IFN-free therapy with sofosbuvir in interferon-ineligible patients with advanced cirrhosis (2015) (2)
Performance of Roche qualitative HEV assay on the cobas 6800 platform for quantitative measurement of HEV RNA. (2020) (2)
Interim results of a Phase Ib / IIa study of the entry inhibitor myrcludex B in chronic hepatitis D infected patients (2016) (2)
Standard coagulation tests are superior to thromboelastometry in predicting outcome of patients with liver cirrhosis (2020) (2)
T cell receptor repertoires within liver allografts are different to those in the peripheral blood. (2020) (2)
375 HEPATITIS B SURFACE ANTIGEN CONCENTRATION IN HEPATITIS B/C CO-INFECTION (2009) (2)
Integrated efficacy analysis of 24-week data from two phase 2 and one phase 3 clinical trials of bulevirtide monotherapy given at 2 mg or 10 mg dose level for treatment of chronic hepatitis delta (2022) (2)
Management of patients coinfected with HBV and HCV (2010) (2)
41 S-Collate COHORT ‘REAL-LIFE’ STUDY: EFFICACY AND SAFETY OF PEGINTERFERON alfa-2a (40KD) IN 1233 PATIENTS WITH CHRONIC HEPATITIS B ACCORDING TO ASIAN AND CAUCASIAN RACE (2013) (2)
Effect of hepatitis B virus on steatosis in hepatitis C virus co‐infected subjects: A multi‐centre study and systematic review (2018) (2)
Distinct Immune Imprints of Post–Liver Transplantation Hepatitis C Persist Despite Viral Clearance (2021) (2)
Hepatitis C and Metabolic Disorders: Genetics, Mechanism, and Therapies (Clinical and Experimental) (2012) (2)
P0638 : Global epidemiology of hepatitis delta: First data from the hepatitis delta international network (2015) (2)
[PEG-interferons: significance for the treatment of viral hepatitis B and C]. (2001) (2)
Anti-retroviral drugs do not facilitate hepatitis C virus (HCV) infection in vitro. (2012) (2)
The Effect of Immunosuppression on Coagulation After Liver Transplantation (2019) (2)
Bulevirtide treatment of hepatitis D in Germany: multicentre real-world experience (2022) (2)
Treatment of acute hepatitis B with lamivudine vs. placebo: A prospective randomized multicenter trial (2013) (2)
Novel prime-boost immune-based therapy inhibiting both hepatitis B and D virus infections (2022) (2)
Viral Interference of Hepatitis C and E Virus Replication in Novel Experimental Co-Infection Systems (2022) (2)
455 HCV VIRAL KINETICS DURING RIBAVIRIN MONOTHERAPY: RESULTS OF A RANDOMIZED PARTIALLY DOUBLE BLIND PLACEBO CONTROLLED CLINICAL TRIAL (2011) (2)
O1 SAPPHIRE II: PHASE 3 PLACEBO-CONTROLLED STUDY OF INTERFERON-FREE, 12-WEEK REGIMEN OF ABT-450/R/ABT-267, ABT-333, AND RIBAVIRIN IN TREATMENT-EXPERIENCED ADULTS WITH HEPATITIS C VIRUS GENOTYPE 1 (2014) (2)
19 ANTIVIRAL EFFECT OF ENTECAVIR: RESULTS FROM 160 CHRONIC HEPATITIS B PATIENTS IN AN INTERNATIONAL MULTICENTER COHORT STUDY (2009) (2)
Late-breaking abstracts (2007) (2)
Therapie der Hepatitis C (2014) (2)
S3-Leitlinie: Diagnostik und Therapie biliärer Karzinome (2022) (2)
Eradikation des Hepatitis-C-Virus und Verhinderung klinischer Endpunkte (2015) (2)
Ga-68-PSMA-11 PET/CT improves tumor detection and impacts management in patients with hepatocellular carcinoma (HCC) (2021) (2)
Analysis of liver biopsies reveals a strong intrahepatic reduction of HDV and inflammatory markers after treatment with Myrcludex B in combination with Tenofovir in chronic HBV/HDV infected patients (2019) (2)
Hippo signaling counter regulates early innate immunity in hepatocytes exposed to Hepatitis B virus (2020) (2)
Percutaneous Transsplenic Balloon-Assisted Transjugular Intrahepatic Portosystemic Shunt Placement in Patients with Portal Vein Obliteration for Portal Vein Recanalization: Feasibility, Safety and Effectiveness (2022) (2)
The INNO-LiPA HBV-DR assay is superior to sequencing for the detection of YMDD-mutants (2003) (1)
Interruption of nucleos(t)ide analogue therapy in HBeAg negative chronic hepatitis B – A new concept to achieve HBsAg decline? (2015) (1)
Longterm outcome of chronic hepatitis C virus infection in a real-world setting: the German LOTOS study (2011) (1)
Low Risk of Occult Hepatitis B Infection among Vietnamese Blood Donors (2022) (1)
Kinetics and predictive value of HBcrAg, HBV RNA and anti‐HBc during bulevirtide treatment of chronic HDV‐infected patients (2023) (1)
P1109 OVERTREATMENT OF PATIENTS WITH CHRONIC HEPATITIS C (CHC) GENOTYPE 2/3 WITH LOW BASELINE VIRAL LOAD AND RVR: EXPERIENCES IN A REAL WORLD SETTING (2014) (1)
Endoscopic vacuum assisted closure (E-VAC) of upper gastrointestinal leakages (2021) (1)
313 DYNAMIC FLUCTUATION OF VIROLOGICAL MARKERS DURING THE NATURAL COURSE OF HEPATITIS DELTA (2010) (1)
Primary sclerosing cholangitis with moderately elevated serum‐IgG4 – characterization and outcome of a distinct variant phenotype (2021) (1)
Tu2039 TURQUOISE-II: SVR12 Rates of 92%-96% in 380 Hepatitis C Virus Genotype 1-Infected Adults with Compensated Cirrhosis Treated with ABT-450/r/ABT-267 and ABT-333 plus Ribavirin (3D+RBV) (2014) (1)
Bile acid increase during bulevirtide treatment of hepatitis D is not associated with a decline in HDV RNA. (2023) (1)
Performance of HCV-Core Antigen Testing in Liver Transplanted Patients: 1030 (2012) (1)
Partially Restored T Cell Responses in HBEAG-Negative Chronic Patients after Stopping NA therapy (2016) (1)
PD-1/CTLA-4 blockade leads to expansion of CD8+PD-1int TILs and results in tumor remission in experimental liver cancer (2022) (1)
Hepatitis B Virus (2004) (1)
HBV-Infektionen in Deutschland – Versorgungskosten in einem Real-life-Setting (2017) (1)
Detection of HBV-specific memory T cells in healthy seronegative virus-exposed individuals (2002) (1)
Brain metabolic and microstructural alterations associated with hepatitis C virus infection, autoimmune hepatitis and primary biliary cholangitis (2022) (1)
P1238 SVR24 RATE OF 60% IN HCV G1-INFECTED PRIOR NULL RESPONDERS TREATED WITH MERICITABINE (MCB), BOCEPREVIR (BOC) PLUS PEGIFN ALFA-2a/RIBAVIRIN (P/R): RESULTS FROM DYNAMO 1 (2014) (1)
Drei Jahre vertikale Vernetzung im Kompetenznetz Hepatitis : Was können wir aus der Nutzung unterschiedlicher Informationsmedien Lernen? (2006) (1)
Low Serum Cholinesterase Identifies Patients With Worse Outcome and Increased Mortality After TIPS (2021) (1)
Detection of low HCV viremia by repeated HCV RNA testing predicts treatment failure to triple therapy with telaprevir (2013) (1)
Global real-world evidence of sofosbuvir/velpatasvir (SOF/VEL) as a highly effective treatment and elimination tool in underserved patient populations experiencing mental health disorders, incarceration or homelessness (2020) (1)
Die Kosten der Versorgung von Hepatitis C Patienten in Deutschland (2013) (1)
Barrieren der Hepatitis-C-Virus (HCV) Elimination in Deutschland: warum erhalten diagnostizierte Patienten keine Therapie? (2020) (1)
Etablierung und Validierung einer neuen Methode zur HBeAg Quantifizierung in HBeAg positiven Patienten mit chronischer Hepatitis B unter Behandlung mit Telbivudine und Entecavir (2009) (1)
Securing wider EU commitment to the elimination of hepatitis C virus (2022) (1)
Nosocomial infections in female compared with male patients with decompensated liver cirrhosis (2022) (1)
Etablierung einer neuen Ultraschallmethode zur Messung der Lebersteifigkeit – prospektiver Vergleich mit Fibroscan und Leberhistologie (2009) (1)
Aktuelle Arzneimitteltherapie der Hepatitis C (2018) (1)
Kinetics of cellular immune responses during the early phase of IFN + ribavirin therapy of chronic hepatitis C infection (2001) (1)
Induction of innate and adaptive immune responses after stopping NA therapy in HBeAg negative chronic hepatitis B (2015) (1)
Successful retreatment of a patient with chronic hepatitis C genotype 2k/1b virus with ombitasvir/paritaprevir/ritonavir plus dasabuvir (2017) (1)
[Current drug treatment of hepatitis C : Useful therapy algorithms taking into consideration economical aspects]. (2018) (1)
P0576 : Impact of organ and non-organ-specific autoantibodies on the treatment outcome of patients with hepatitis D virus infection (2015) (1)
Metamizole-Associated Risks in Decompensated Hepatic Cirrhosis. (2022) (1)
Reduction of serum infectivity of hepatitis Delta virus-infected patients treated with Myrcludex B: An in vitro assay to determine infectious units (2018) (1)
Identification of patients with compensated cirrhosis who can safely use protease inhibitor-based therapy for HCV infection (2020) (1)
Neue Therapiestrategien bei viralen Hepatitiden (2004) (1)
Primary sclerosing cholangitis as an independent risk factor for cytomegalovirus infection after liver transplant (2020) (1)
749 Role of the Cirrhosis Risk Score (CRS) for the Prediction of Fibrosis Progression in Hepatitis C Patients with Minimal Liver Disease (2009) (1)
UEG Week Vienna 2014 cutting edge symposium: Today’s Science, Tomorrow’s Medicine session features the immune system – a driving force in digestive health and disease (2014) (1)
[549] INJURY WITH HEPATITIS C (HCV)-CONTAMINATED NEEDLES IN HEALTH CARE WORKERS: WHAT IS THE TRUE RATE OF SEROCONVERSION? (2007) (1)
The incidence of hepatocellular carcinoma in hepatitis B virus infected persons of different origins, living in Sweden (2018) (1)
Early lamivudine therapy prevents liver failure in patients with fulminant hepatitis B (2002) (1)
Can HCV core antigen replace HCV RNA testing in the era of direct-acting antivirals? (2017) (1)
Triple therapy for hepatitis C virus (HCV) infection: Eligibility, safety and efficacy in a real world setting (2013) (1)
Cardiogenic shock due to a spontaneously ruptured pheochromocytoma: a rare but life-threatening event—a case report (2022) (1)
Can response to pegylated interferon treatment in chronic delta hepatitis be predicted with on-treatment parameters? (2012) (1)
Use of the 6 million viral load cut-off to guide treatment duration with ledipasvir/sofosbuvir in patients with chronic hepatitis C virus genotype 1 infection: results from the German Hepatitis C-Registry (DHC-R) (2017) (1)
744 TREATMENT OF MULTIRESISTANT HBV PATIENTS WITH ENTECAVIR PLUS TENOFOVIR. 2 YEARS SAFETY AND EFFICACY ANALYSIS. AN INTERNATIONAL MULTICENTER COHORT STUDY (2011) (1)
FRI-175-Frequency, severity and impact of Peg-IFNa-associated flares in HDV infection: Results from the HIDIT-II study (2019) (1)
Antimicrobial resistance in patients with decompensated liver cirrhosis and bacterial infections in a tertiary center in Northern Germany (2021) (1)
1033 QUANTITATIVE SERUM HBEAG MONITORING DURING TELBIVUDINE TREATMENT CORRELATES WITH VIROLOGICAL OUTCOMES (2010) (1)
Correction: Safety and efficacy of prophylactic and therapeutic vaccine based on live-attenuated Listeria monocytogenes in hepatobiliary cancers (2022) (1)
Commentary: detection of low level viraemia in telaprevir‐based triple therapy for hepatitis C virus – authors' reply (2014) (1)
931 PREDICTION OF LONG-TERM SURVIVAL IN CHRONIC HEPATITIS C PATIENTS WITH ADVANCED FIBROSIS USING STANDARD LABORATORY TESTS (2012) (1)
A human monoclonal antibody against HBsAg for the prevention and treatment of chronic HBV and HDV infection (2022) (1)
Liver-first strategy for a combined lung and liver transplant in patients with cystic fibrosis. (2021) (1)
Longterm Benefits of Sustained Virological Response (SVR) in Patients With Chronic Hepatitis C (CHC) Virus Infection: The German Lotos Study (2011) (1)
Home-Based Management of Refractory Ascites by Permanent Tunneled Peritoneal Catheter is an Effective Replacement for Recurrent Large Volume Paracentesis (2016) (1)
Low Risk of Developing Chronic Hepatitis E in Heart Transplant Recipients: A Prospective 2-Year Follow-Up Study (2017) (1)
Baseline bile acid levels but not bile acid increases during bulevirtide treatment of hepatitis D are associated with HDV RNA decline (2022) (1)
P671 INCREASED ANTI HEV SEROPREVALENCE RATES IN HEART TRANSPLANT RECIPIENTS: COMPARISON OF TWO SEROASSAYS (2014) (1)
Association between liver cirrhosis and cardiovascular events in a large German cohort-a population based study (2022) (1)
Effects on health-related quality of life of interferon-free antiviral therapy for chronic hepatitis C infection – Results from the German Hepatitis C-Registry (DHC-R) (2019) (1)
Clinical significance of drug-drug interactions during HCV therapy with sofosbuvir and simeprevir in comparison to first wave protease inhibitors (2015) (1)
Therapie der Hepatitis-C-Infektion (2001) (1)
Early monotherapy with pegylated interferon alfa–2b for acute hepatitis C infection: Final Results of the German HEP-NET Acute HCV II Study (2005) (1)
P667 HEPATITIS B CORE-RELATED ANTIGEN (HBcrAg) LEVELS IN THE NATURAL HISTORY OF HEPATITIS B INFECTION IN A LARGE EUROPEAN COHORT (2014) (1)
Aktuelle Empfehlung zur Therapie der chronischen Hepatitis C (2014) (1)
Bile acid monitoring to support safety and efficacy of Myrcludex B in combination with Tenofovir in patients with chronic HBV/HDV co-infection (2018) (1)
A virological response to PEG-IFNa treatment of hepatitis delta is associated with an improved clinical long-term outcome: 10 years follow-up of the HIDIT-1 study (2018) (1)
Treatment of Acute Hepatitis C (2006) (1)
HLA class II donor specific antibodies are associated with graft cirrhosis after liver transplant independent of the mean fluorescence intensity level (2020) (1)
Viral hepatitis after liver transplantation. Which immunosuppressive drugs should be recommended? (2007) (1)
A rapid point-of-care device for the diagnosis of Hepatitis Delta Virus infection (2019) (1)
Transjugular liver biopsy and hepatic venous pressure gradient measurement in patients with and without liver cirrhosis. (2020) (1)
Bulevirtide improves health-related quality of life measured by EQ-5D VAS in patients with chronic hepatitis delta: An exploratory analysis of a Phase 3 trial at 48 weeks (2023) (1)
Recently acquired and early chronic hepatitis C in MSM: Recommendations from the European treatment network for HIV, hepatitis and global infectious diseases Consensus panel: Erratum. (2020) (1)
Low anti‐HBc levels are associated with lower risk of virological relapse after nucleos(t)ide analogue cessation in HBe antigen‐negative patients (2022) (1)
Asian and White Patients With Chronic Hepatitis C (CHC) Achieve Similar Response Rates With Peginterferon (PEG-IFN) Alfa-2b Plus Ribavirin (RBV) in Genotypes (G) 2 and 3: Subanalysis of the REDD 2/3 Study (2009) (1)
Long-term persistence of HCV resistance-associated substitutions after DAA treatment failure. (2022) (1)
[Paradigmatic change in treatment of viral hepatitides]. (2012) (1)
711 SERUM CYTOKINE LEVELS DURING PEG-IFNA-2a +/− ADEFOVIR TREATMENT OF DELTA HEPATITIS: RESULTS FROM THE HEP-NET/INTERNATIONAL HIDIT-1 STUDY (2008) (1)
150 – Acute Viral Hepatitis (2012) (1)
P0668 : On-treatment HBsAg kinetics to predict long-term HDV RNA response to peg-IFNa treatment of hepatitis delta (2015) (1)
Recombinant Technology Peptide – h 2-microglobulin – MHC fusion molecules bind antigen-specific T cells and can be used for multivalent MHC – Ig complexes (2002) (1)
Cytotoxic CD4-positive T cells in viral hepatitis (2004) (1)
Improved Platelet Count and Smaller Spleen Size Long After Sustained Virological Response in Chronic Hepatitis C Patients With Advance Fibrosis (2011) (1)
An unusual cause of erythema on both lower legs in a patient with Crohn´s disease. (2021) (1)
Reply to: “Progressive cholangiopathy in COVID-19 patients: Other possible diagnoses than ketamine-induced cholangiopathy should be considered” (2021) (1)
62 PHASE II HCVac STUDY OF TG4040 IMMUNOTHERAPEUTIC IN COMBINATION WITH PEGIFNa2a AND RIBAVIRIN IN GENOTYPE 1 CHC TREATMENT NAÏVE PATIENTS: SVR24 FINAL RESULTS (2013) (1)
Detection of low amounts of HCV-RNA in the serum of sustained virological responders after antiviral therapy (2007) (1)
Hepatitis-A- und -E-Virus-Infektionen – Altes und Neues (2020) (1)
Dominance of HCV in HBV/HCV co-infected patients is associated with lower quantitative HBsAg and higher serum IP-10 levels (2013) (1)
Systematic Review with Meta-Analysis: Efficacy and Safety of Lusutrombopag for Severe Thrombocytopenia in Patients with Chronic Liver Disease Undergoing Invasive Procedures (2022) (1)
Utility of the new cobas HCV test for viral load monitoring during direct-acting antiviral therapy (2019) (1)
[Joint opinion of the German Society of Gastroenterology, Digestive and Metabolic Diseases (DGVS) and the German Society for Internal Medicine (DGIM) to Daclatasvir-benefit assessment according to § 35a SGB V the G-BA]. (2015) (1)
P0781 : High SVR rates despite multiple negative predictors in genotype 1 patients receiving ombitasvir/paritaprevir/R, dasabuvir with or without ribavirin for 12 and 24 weeks: Integrated analysis of six phase 3 trials (2015) (1)
Rheumatological Patients are at Risk of Chronic HEV Infection: A Multicentric European Study (2016) (1)
P0606 : TNF-alpha significantly inhibits hepatitis E virus replication (2015) (1)
[98] EFFECTOR/MEMORY SUBSETS AND FUNCTIONALITY OF CD4/CD8+ T-CELLS DURING POTENT ANTIVIRAL THERAPY IN CHRONIC HEPATITIS B (CHB) (2007) (1)
HBV RNA levels are associated with virological response to treatment with pegylated interferon alpha in patients with chronic hepatitis D virus infection (2022) (1)
565 RIBAVIRIN TREATMENT OF HEV INFECTION IN IMMUNOCOMPETENT AND IMMUNOCOMPROMISED PATIENTS: WHICH PATIENTS NEED ANTIVIRAL THERAPY? (2012) (1)
Membrane-bound IL-2 improves the expansion, survival, and phenotype of CAR Tregs and confers resistance to calcineurin inhibitors (2022) (1)
Hepatitis B virus: where are we and where are we going? (2004) (1)
444 Quasispecies evolution in chronic hepatitis C patients after immunization with the therapeutic vaccine IC41 (2006) (1)
358 COMPARING THE LONG-TERM OUTCOME OF HEPATITIS DELTA AND HBV MONOINFECTION: IS HDV-INFECTION REALLY WORSE? (2011) (1)
Differential cytokine pattern of HDV-specific cellular immune responses: Results from the hep-net/international HIDIT-1 study (2007) (1)
Adefovir serum levels do not differ between responders and nonresponders (2011) (1)
The widespread rarity of HBsAg loss in chronic hepatitis B. (2019) (1)
P043: Injecting drug users (IDUs) are prone to Hepatitis B because of the high risk behaviour. Hepatitis B can be prevented through vaccines but the IDUs and their sexual partners from Kathmandu, Nepal are not getting preventive hepatitis B vaccinations (2015) (1)
Plasma and ascites pharmacokinetic of meropenem in patients with decompensated liver cirrhosis and spontaneous bacterial peritonitis. (2021) (1)
Serum cytokines and HBsAg decline in patients with acute Hepatitis B Virus (HBV) infection (2013) (0)
HEV genomic insertions identified in chronic patients enhance viral fitness (2023) (0)
Hepatitis B virus surface antigen inactivates the hippo pathway and thereby increases the hepatic expression of oncogene BMI1 (2020) (0)
Chronic hepatitis C virus infection irreversibly impacts human natural killer cell repertoire diversity (2018) (0)
State-of-the-Art Lecture: Treatment of hepatitis C (2009) (0)
Quantification of Large, Middle and Small Hepatitis B virus (HBV) surface protein (HBsAg) fractions in patients with Hepatitis Delta (2014) (0)
Chronic hepatitis E in lung transplant recipients (2013) (0)
IFN-alpha activated NK cells require DNAM-1 for recognition of infected cells during acute HCV infection (2010) (0)
P0789 : Effectiveness, safety and cost per SVR in GT4 hepatitis C patients treated with sofosbuvir-based therapies in real clinical practice: A Franco-German experience (SOFEX-4) (2015) (0)
Dynamics of natural killer cell responses to hepatitis delta virus infection during the course of interferon alpha treatment (P6070) (2013) (0)
Patients with chronic HCV and decompensated cirrhosis are at risk for MELD purgatory (2022) (0)
COMPREHENSIVE IMMUNOPHENOTYPING OF TREGS AND SERUM CYTOKINES MAY HELP TO DISTINGUISH HCV HEPATITIS FROM REJECTION IN LIVER TRANSPLANT PATIENTS (2012) (0)
E-xchange: Hepatitis E and the Risk of Plasma Products for Organ Transplant Recipients. (2018) (0)
292 ASSOCIATION OF HBSAG DECLINE WITH INNATE AND ADAPTIVE IMMUNE RESPONSES DURING ACUTE HEPATITIS B VIRUS INFECTION (2011) (0)
A prospective multicenter pilot study to investigate the efficacy of pegylated Interferon-α2b and ribavirin in HBsAg+/HCV-RNA+ patients: The HEP-NET B/C coinfection trial (2008) (0)
548 UNEXPECTED INCREASE OF HEPATITIS B SURFACE ANTIGEN (HBSAG) CONCENTRATIONS DURING TREATMENT WITH NUCLEOS(T)IDE ANALOGUES 12-24 MONTHS BEFORE VIROLOGICAL BREAKTHROUGH AND RESISTANCE (2012) (0)
Clinical management of viral coinfections (2010) (0)
A NOVEL IMMUNOSUPPRESSIVE FUNCTION OF ANTI-IL-2 RECEPTOR ANTIBODIES: IMPAIRMENT OF ANTIGEN UPTAKE AND T CELL STIMULATION OF HUMAN MYELOID DENDRITIC CELLS BY BASILIXIMAB IN VITRO AND IN VIVO (2004) (0)
Patients with Chronic Hepatitis C Can be Identified by their Gut Microbiota (2016) (0)
P0073 : Individualizing hbig reinfection prophylaxis after HBV-induced liver transplantation: Results from a mathematical modeling approach based on clinical data (2015) (0)
642 CHARACTERISATION OF HEPATITIS C VIRUS ENTRY AND RNA REPLICATION IN CELLS OF CNS ORIGIN (2010) (0)
Estimating the prevalence of hepatitis delta infection among foreign-born adults with chronic hepatitis B in the United States (2022) (0)
Genotype-specific expression system of Hepatitis C Virus glycoproteins for efficient viral particle complementation (2013) (0)
Frequency and functional analysis of variants of the immunodominant epitope NS3–1073: Relevance for vaccine design (2006) (0)
[Evolution of hepatitis C virus genotype 1a vs. 1b distribution in Germany between 2004 and 2018 - An analysis of 17093 patients from different real world registries]. (2021) (0)
872 IMPACT OF ANTI-RETROVIRAL AGENTS ON SUSCEPTIBILITY TO AND REPLICATION OF HEPATITIS C VIRUS IN VITRO (2012) (0)
[Hepatitis E - More than a Rare Travel-Associated Infectious Disease!] (2017) (0)
P0707 : Differences in the intestinal microbiota in patients with chronic hepatitis C (2015) (0)
HDV infection rates in northern Vietnam (2018) (0)
A novel class of glycan-specific human monoclonal antibodies neutralizing the hepatitis E virus (2022) (0)
Abstract 5412: CCR4+CCR6+Th17 cells suppress autologous CD8+ T cell responses in patients with hepatocellular carcinoma (2012) (0)
Unexpected increase of Hepatitis B Surface Antigen (HBsAg) levels during treatment with nucleos(t)ide analogous 12–24 months before virological breakthrough and resistance (2012) (0)
Correction to: Real-World Clinical Practice Use of 8-Week Glecaprevir/Pibrentasvir in Treatment-Naïve Patients with Compensated Cirrhosis (2020) (0)
Relevance of quantitative HBsAg (qHBsAg) during long-term treatment of chronic hepatitis B with nucleos(t)ide analogues (NUCs) (2011) (0)
P660 THE EFFECT OH HEPATITIS B VIRUS INFECTION ON STEATOSIS IN HEPATITIS C VIRUS COINFECTED PATIENTS: THE BOSTIC STUDY (2014) (0)
Hippo inactivation drives BMI1-associated proliferative hepatocarcinogenesis in chronic hepatitis B virus infection (2022) (0)
O.180 Longer survival of liver transplant recipients with hepatitis virus coinfections (2006) (0)
Diet-refractory NASH in an elderly woman (2020) (0)
Hepatitis B virus-replicating transgenic mice exhibit a functional but restricted responsiveness to exogenous Tlr3 and Rig-I stimuli (2022) (0)
Risk Factors and Seroprevalence of Hepatitis E in Pregnant and Non-Pregnant Women in a Southern Region of Brazil (2016) (0)
Partnering for cure meeting in Stockholm (2015) (0)
O118 A MUTATION IN THE HEPATITIS E VIRUS POLYMERASE ASSOCIATED WITH RIBAVIRIN TREATMENT FAILURE HAS A REPLICATION ADVANTAGE IN VITRO (2014) (0)
P1210 PREDICTORS OF SVR24 FOR 1078 PATIENTS WITH SEVERE FIBROSIS OR COMPENSATED CIRRHOSIS: THE INTERNATIONAL TELAPREVIR ACCESS PROGRAM (2014) (0)
393 Impaired trail-dependent cytotoxicity of CD1C-positive dendritic cells in chronic hepatitis C virus infection (2004) (0)
811 RESPONSE TO TREATMENT FOLLOWING RECENTLY ACQUIRED HEPATITIS C VIRUS INFECTION (2013) (0)
IL-28B Genotype is not associated with early HCV-RNA negativity in patients with symptomatic acute HCV infection (2013) (0)
Ultrasound detected perihepatic lymphadenopathy and response to inferferon alpha in chronic hepatitis C (1998) (0)
284 COMPREHENSIVE PHENOTYPING OF IMMUNE CELLS IN CHRONIC HEPATITIS DELTA (2011) (0)
638 PARVOVIRUS B19 INFECTION: EVIDENCE FOR INTRAHEPATIC LONG-TERM PERSISTENCE BUT NO ASSOCIATION WITH DISEASE PROGRESSION IN CHRONIC HEPATITIS C (2008) (0)
Reply to: "HCV RNA kinetics on-treatment do not predict sustained virologic response in HCV genotype 3 patients receiving sofosbuvir and ribavirin". (2016) (0)
ORIGINAL ARTICLES—LIVER, PANCREAS, AND BILIARY TRACT Prognostic Implications of Lactate, Bilirubin, and Etiology in German Patients With Acute Liver Failure (2008) (0)
Reply to the Letter to the Editor: “Comparison of the Safety and Efficacy of Yttrium-90 Radioembolization for Nonalcoholic Fatty Liver Disease-Associated and Hepatitis B Virus-Associated Hepatocellular Carcinoma” (2020) (0)
Application of CT-contrast media is not associated with a higher risk for acute kidney injury in patients with decompensated liver cirrhosis (2022) (0)
Comparison of treatment duration in patients infected with genotype 1/4 between 2003–2007 and 2008–2011 period. (2015) (0)
A175 CAN HCV CORE ANTIGEN REPLACE HCV RNA TESTING IN THE ERA OF DIRECT-ACTING ANTIVIRALS? (2018) (0)
Association between low anti-HBc level and lower risk of virological relapse after nucleos(t)ide analogue cessation in HBe antigen negative chronic hepatitis B patients (2022) (0)
P1208 PREDICTION OF SEVERE CUTANEOUS REACTION DURING TRIPLE THERAPY IN HCV: VALIDATION OF A GWAS CANDIDATE GENETIC MARKER (2014) (0)
Famciclovir improves liver histology in immunosuppressed patients with chronic hepatitis B (1998) (0)
Treatment of Hepatitis E in Solid Organ Transplant Recipients: 1751 (2012) (0)
P122: Type I interferon elevates co‐regulatory receptor expression on CMV‐ and EBV‐specific CD8 T cells in Chronic Hepatitis C (2015) (0)
438 BASELINE AND WEEK 24 HBeAg LEVELS ARE ASSOCIATED WITH TELBIVUDINE TREATMENT RESPONSE IN THE 2410 ROADMAP STUDY IN CHRONIC HEPATITIS B (2013) (0)
O‐27: Early HCV RNA kinetics predict relapse to sofosbuvir/ribavirin dual therapy (2015) (0)
Regression of a CD30-Positive Primary Cutaneous T-Cell Lymphoproliferation after Ribavirin Treatment of Chronic Hepatitis E Virus Infection (2016) (0)
Immune Responses in Acute and Chronic Hepatitis C (2007) (0)
The Hippo signalling is induced by Toll-like receptor 4 activation and regulatory balance innate immune responses in liver cells (2019) (0)
P722 PERFORMANCE AND VALUE OF IFN-LAMBDA3 AND IFN-LAMBDA4 GENOTYPING IN PATIENTS WITH CHRONIC HEPATITIS C (CHC) GENOTYPE 2/3 IN A REAL WORLD SETTING (2014) (0)
Disease progression is affected by pattern of serum alanine aminotransferase dynamics in a cohort of patients with hepatitis B e antigen-negative chronic infection: 4 years follow-up of a prospective longitudinal study (ALBATROS study) (2018) (0)
Modulation of HCV reinfection by fibroblast growth factor-2 and other non-interferon mediators (2015) (0)
P0565 : Cytokine patterns of patients with HCV/HBV co-infection (2015) (0)
[476] PREVALENCE OF HBV GENOTYPES IN CENTRAL AND EASTERN EUROPE (2007) (0)
Large scale biomarker profiling reveals distinct cytokine and chemokine signatures distinguishing different acute and chronic hepatitis virus infections (2015) (0)
346 COMPRISED FUNCTION OF NATURAL KILLER CELLS IN ACUTE AND CHRONIC VIRAL HEPATITIS (2013) (0)
P061: Interruption of nucleos(t)ide analogue therapy in HBeAg‐negative chronic hepatitis B ‐ a new concept to achieve HBsAg reduction? (2015) (0)
Declining HIV Drug Resistance in Europe (2013) (0)
P069: Risk factors associated with type 2 diabetes mellitus in patients with chronic hepatitis B: a cross‐sectional study with pair‐matched controls (2015) (0)
From Volcano Clouds to iLivers: Growing EASL in times of change (2010) (0)
Long-Term HDV-RNA Suppression - HBsAg Clearance in Chronic Hepatitis D Following Interferon Therapy (2014) (0)
Whole genome deep sequencing is superior to sequencing only regions of special interest for the characterization of HDV evolution (2017) (0)
Brain metabolic and microstructural alterations associated with HCV infection, AIH and PBC. (2021) (0)
Hepatitis E virus-specific T cell responses against non-structural viral proteins in patients with ongoing and resolved hepatitis E (2017) (0)
Sclerotherapy of Symptomatic Nonparasitic Splenic Cysts: Excellent Long-Term Treatment Response' (2022) (0)
The HCV drug-rally is ongoing: Simeprevir and Daclatasvir approved by EMA! (2014) (0)
433 QUANTIFICATION OF LARGE, MIDDLE AND SMALL HEPATITIS B VIRUS (HBV) SURFACE PROTEIN (HBsAg) FRACTIONS IN PATIENTS WITH ACUTE HEPATITIS B (2013) (0)
P179: Plasma cytokine and chemokine patterns during PEG‐IFNa‐2a therapy of chronic hepatitis delta (2015) (0)
FIB-4 and APRI-scores predict survival in patients with transjugular intrahepatic portosystemic stent shunts (2020) (0)
A novel mid-scale screening assay to identify compounds with anti-HDV activity (2017) (0)
[465] TRAIL-EXPRESSION ON NK CELL SUBSETS IN RESPONSE TO TYPE-I-INTERFERONS IN VIRAL HEPATITIS (2007) (0)
P060: Incidence of hepatocellular carcinoma in chronic hepatitis B patients responders to nucleoside analogue treatment (2015) (0)
Adenosine and interferon alpha synergistically increase IFN-gamma production of PBMC via the A3-receptor (2007) (0)
Akute Hepatitis C – Therapie mit Interferon α-2b (2002) (0)
mRNA based expression of Hepatitis E specific neutralizing antibodies in liver cells as therapeutic option (2023) (0)
Expandable constrained 6 mm transjugular intrahepatic portosystemic shunt: an alternative approach for high-risk patients? (2022) (0)
Anti-HDV-IgM testing in hepatitis delta revisited: Correlations with disease activity and response to pegylated interferon alfa-2a treatment (2010) (0)
Inhibition of antigen-specific CD8+ T cell proliferation using peptide pools- Possible mechanisms (2009) (0)
Multicentric performance analysis of HCV quantification assays and its potential relevance for HCV treatment (2015) (0)
O314: HCV contributes to the aggravation suppressive activity of natural regulatory T cells and induces the emergence of type 1 regulatory T cells (2014) (0)
Role of BMI, age and sex for disease severity in acute hepatitis C: Analysis of 254 patients from the German Hep-Net acute HCV cohort (2008) (0)
Predictors of HBsAg loss after cessation of nucleo (s)tide analogue therapy in asian patients with low HBsAg levels (2022) (0)
Kinetic of Hepatitis B core-related antigen (HBcrAg) levels in chronic hepatitis B during NUC therapy (2015) (0)
Comprehensive characterization of Mucosal-Associated invariant T (MAIT) cells in patients with hepatitis E virus infection (2022) (0)
Characterization of in-vitro responses to immune modulation of HBV core 18 -specific vs HBV pol455-specific CD8+ T cells (2021) (0)
Long-term outcome of hepatitis delta compared to HBV monoinfection (2018) (0)
P185: Cellular immune responses in persistent hepatitis delta virus infection (2015) (0)
Severe acute respiratory syndrome coronavirus type 2 (SARS-CoV-2) specific cellular and humoral immunity in Corovavirus Disease-2019 (COVID-19) convalescence after liver transplantation-a prospective six month follow-up (2022) (0)
Integrated safety analysis of 24-week data from three phase 2 and one phase 3 clinical trials of bulevirtide monotherapy given at 2 mg and 10 mg dose level for treatment of chronic hepatitis delta (2022) (0)
45 IMMUNE EVASION OF HEPATITIS DELTA FROM CD8+ T CELL IMMUNE RESPONSE (2013) (0)
1058 Real World Effectiveness and Safety of Glecaprevir/Pibrentasvir in Adults With Chronic Hepatitis C Virus Infection: A Meta-Analysis (2019) (0)
The role of HDV in the natural history of the persistent HBV infection (2011) (0)
Factors predicting clinical endpoints in Hepatitis Delta: A retrospective-prospective single center study (2013) (0)
547 PERFORMANCE OF HCV-CORE ANTIGEN TESTING IN LIVER TRANSPLANTED PATIENTS (2011) (0)
Immunopathogenesis of Hepatitis D (2014) (0)
P0053 : Dinstict intrahepatic cytokine profiles for the differentiaton of acute cellular rejection vs recurrent hepatitis C in liver transplanted patients (2015) (0)
426 Dynamics of CD81-expression on lymphocyte subsets during antiviral treatment of patients with chronic hepatitis C (2006) (0)
P145: Improvement of liver function parameters in advanced HCV‐associated liver cirrhosis during IFN‐free antiviral therapy (2015) (0)
NK cell responses during direct-acting antiviral treatment of chronic hepatitis C virus infection (2016) (0)
317 DISTINCT T CELL RESPONSES AND CYTOKINE PATTERN IN HEPATITIS DELTA (2010) (0)
The impact of adipokines hormones on HCV life-cycle (2014) (0)
P095: High‐resolution determination of human hepatic immune cell signatures from fineneedle liver aspirates (2015) (0)
Clinical Utility of Hepatitis B Core-Related Antigen (HBcrAg) in the Treatment of Hepatitis Delta (2016) (0)
Everolimus combined with low-dose tacrolimus controls histological graft injury and liver fibrosis as sufficiently as high-dose tacrolimus combined with mycophenolate after liver transplantation (2022) (0)
[540] FREQUENCY AND SIGNIFICANCE OF VERY LOW HCV VIREMIA DETECTED BY A HIGHLY SENSITIVE HCV-RNA ASSAY (2007) (0)
[Interferon-alfa induced reactivation of sarcoidosis in a patient with chronic hepatitis C]. (2010) (0)
Clinical characteristics of patients with non-alcoholic fatty liver disease (NAFLD) in Germany – First data from the German NAFLD-Registry (2022) (0)
Real-world evidence on all-oral, interferon-free regimens with Ombitasvir/Paritaprevir/r and Dasabuvir for treatment of chronic HCV patients receiving opioid substitution therapy in the German Hepatitis C-Registry (2016) (0)
Efficacy and safety of Telaprevir in patients with hepatitis C genotype 1 infection: The German Telaprevir early access program (2014) (0)
P105: Intestinal microbiota in chronic hepatitis C: Differences in microbial communities in patients with and without liver cirrhosis (2015) (0)
SIMULTANEUS DETECTION OF OXIDIZED AND NITRATED OLEIC ACID METABOLITES IN PATIENTS WITH CHRONIC LIVER DISEASE (2011) (0)
Letter from the Editor Dear Colleagues (2014) (0)
Systemic inflammation and altered NK and T cell activation drive neuro-psychiatric symptoms manifested by chronic hepatitis C and autoimmune patients (2017) (0)
Endoscopic vacuum-assisted closure therapy for leakage of the lower gastrointestinal tract: multicenter experiences (2022) (0)
No virologic resistance to bulevirtide monotherapy detected in patients through 24 weeks treatment in phase II and III clinical trials for chronic hepatitis delta. (2023) (0)
Diagnostik der Hepatitis C Virus Infektion: Rolle des HCV-Core Antigen Assay (2015) (0)
Identification of a highly cross-reactive CD8+ T cell repertoire that recognizes a hepatitis E virus peptide and an apoptotic epitope (2017) (0)
Sustained HCV-RNA response and HBs-seroconversion after individualized antiviral therapy with pegylated interferon alpha plus ribavirin and active vaccination in an HCV/HBV-coinfected patient (2007) (0)
193 PROGNOSTIC SERUM BIOMARKERS FOR GRAFT SURVIVAL AFTER LIVER TRANSPLANTATION IN HEPATITIS C PATIENTS (2012) (0)
Viral Dominance patterns in hepatitis delta patients are associated with distinct systemic inflammatory patterns which influence response to interferon therapy (2017) (0)
287 COMPREHENSIVE PHENOTYPING OF REGULATORY T CELLS FROM PATIENTS AFTER LIVER TRANSPLANTATION REVEALS DISTINCT T-REG PROPERTIES ASSOCIATED WITH GRAFT HEPATITIS AND REJECTION (2011) (0)
The application of immunoglobulins after liver transplantation influences the occurrence of donor-specific antibody associated complications (2020) (0)
Management of hepatitis B virus infection: Impact of migrational background, education and household income (2010) (0)
Effects of anti-TNF? treatment on Crohn’s disease induced hepatic steatosis (2020) (0)
621 LACK OF CORRELATION BETWEEN PD-1 EXPRESSION ON T CELLS AND CLINICAL PARAMETERS FROM PATIENTS WITH CHRONIC HEPATITIS C (2008) (0)
Individuals with migrational background showed high prevalence of hepatitis marker: A prospective screening approach in primary care centers (2013) (0)
Author Correction: Development and performance of prototype serologic and molecular tests for hepatitis delta infection (2020) (0)
Apoptosis sensitivity of hepatocellular carcinoma to sorafenib-based treatment combinations depends on the expression pattern of BH3-only proteins (2022) (0)
Lack of full re-constitution of exhausted HCV-specific CD8+ T cells following IFN-free DAA therapy is partially reversed upon immune check-point inhibitions during chronic HCV (2017) (0)
High SVR 12 rates following treatment with direct acting antiviral agents (DAA) in a German multicentre cohort of HCV/HIV-1 coinfected patients on the transplant waiting list with advanced liver cirrhosis (2017) (0)
995 CYTOKINE AND CHEMOKINE PATTERNS IN HEPATIC VEIN SERUM DISTINGUISH PATIENTS WITH ACUTE LIVER FAILURE FROM OTHER LIVER DISEASES (2013) (0)
HBsAg decline after interrupting nucleos(t)ide analogue therapy in HVeAg-negative chronic hepatitis B (2015) (0)
IN VITRO AND IN VIVO INVESTIGATIONS ON THE EFFECTS OF CYCLOSPORINE ON HUMAN DENDRITIC CELL SUBSETS (2004) (0)
299 EXPRESSION OF THE 2B4 ADAPTOR MOLECULE SAP AS A DETERMINANT FOR CD8+ T CELL FUNCTION AND DYSFUNCTION IN VIRAL HEPATITIS (2011) (0)
228 GB-VIRUS-C VIREMIA AFTER LIVER TRANSPLANTATION IS ASSOCIATED WITH BETTER 10-YEAR-SURVIVAL (2008) (0)
SAT-204-Hepatitis E virus antigen in urine as a useful diagnostic Background and aims: for monitoring infection and detection of recent infection (2019) (0)
Differential expression of perforin in T-cells during interferon therapy of acute hepatitis C (2006) (0)
799 EFFECTS OF RIBAVIRIN ON NK CELL PHENOTYPE AND FUNCTION IN HEPATITIS C VIRUS INFECTION (2012) (0)
Single cell analysis of HCV and heterologous virus-specific CD8+T cell responses in patients with chronic hepatitis C before and after HCV elimination (2023) (0)
Application of CT contrast medium is not associated with an increased risk for acute kidney injury in patients with decompensated cirrhosis (2022) (0)
627 IN VITRO PROLIFERATION OF ANTIGEN-SPECIFIC CD8+ T CELLS CAN BE INHIBITED BY USING PEPTIDE POOLS (2008) (0)
Comprehensive analysis of NK cell phenotype and function during the initial phase of antiviral therapy: distinct roles of Ribavirin and Interferon alpha (2013) (0)
Biomarkers to predict the clinical outcome of hepatitis delta (2015) (0)
Predictors of Response To Intra-Arterial Vasodilatory Therapy of Non-Occlusive Mesenteric Ischemia In Patients With Severe Shock - Results From A Prospective Observational Study (2022) (0)
CS1-03 Immunological Effects of Type I Interferons in Hepatitis B Revisited: How Does Interferon Work against HBV? (2009) (0)
Long-term kinetics of quantitative HBsAg levels during successful oral antiviral therapy of chronic hepatitis B (2007) (0)
IDDF2019-ABS-0212 Real-world effectiveness and safety of glecaprevir/pibrentasvir in adults with chronic hepatitis C virus infection: a meta-analysis (2019) (0)
14 Cross-genotype-reactivity of the immunodominant HCV-CD8 T-cell epitope NS3-1073: Significance for the development of peptide-based vaccines against HCV (2006) (0)
435 ANTI-HDV-IgM AS A MARKER OF DISEASE ACTIVITY IN HEPATITIS DELTA (2013) (0)
K.02 Re-emerging epidemiology of hepatitis virus infections in Europe? (2008) (0)
Low Prevalence of HEV Infection and No Associated Risk of HEV Transmission from Mother to Child among Pregnant Women in Vietnam (2021) (0)
Measurement of IgG4 in bile: A new approach to diagnose IgG4-associated cholangiopathy (2012) (0)
[Three years of vertical networking in the German Network of Competence on Viral Hepatitis: what can we learn from the usage of different information tools?]. (2006) (0)
355 APPLYING HEPATITIS B GUIDELINES IN EUROPE: HOW EXPENSIVE IS A STATE-OF-THE ART MANAGEMENT OF HBV INFECTION? (2011) (0)
P708 CHRONIC HEPATITIS E – THE SPECTRUM OF HISTOPATHOLOGY (2014) (0)
P153 NK-CELL FREQUENCY AND PHENOTYPE AFFECT THE OUTCOME OF ACUTE HEPATITIS VIRUS C INFECTION (2014) (0)
P178: Quantitative HBsAg level and its potential applications in patients with hepatitis D coinfection (2015) (0)
760 ENTECAVIR TREATMENT IS EFFECTIVE IN PATIENTS WITH PREVIOUS ADEFOVIR TREATMENT: RESULTS FROM AN INTERNATIONAL MULTICENTER COHORT STUDY (2011) (0)
527 Cytotoxic CD4+ T cells in viral hepatitis (2004) (0)
Clinical impact, morbidity and mortality of Hepatitis E at tertiary referral centres in central Europe (2018) (0)
TIPS insertion leads to partial reversal of systemic inflammation in patients with decompensated liver cirrhosis (2022) (0)
3P and 5P model of limited value for the detection of clinically significant portal hypertension in patients with hepatitis delta. (2023) (0)
Reverse Inflammaging: Biological age is accelerated in chronic HCV patients and decelerates after HCV cure (2022) (0)
Effect of immunosuppressive drugs on regulatory T cells after liver transplantation (2013) (0)
419 INACTIVATION OF HEPATITIS C VIRUS BY DISINFECTANTS AND HEAT (2009) (0)
Real World Experience of Prescribing Tenofovir Alafenamide for Chronic Hepatitis B Patients in Germany (2019) (0)
P139: Development of treatment model for HIV/HCV co‐infected OST patients as the basis for scaling up access to HCV treatment for key populations in Ukraine (2015) (0)
[661] ROLE OF THE CD26/ADA/ADENOSINE SYSTEM IN VIRAL AND AUTOIMMUNE CHRONIC LIVER DISEASES (2007) (0)
Serum biomarker profile can predict the outcome of acute HCV infection (2015) (0)
P0767 : Clinical utility of hepatitis C virus core antigen testing in the monitoring of treatment naïve non-cirrhotic patients receiving an all-oral, interferon-free regimien (2015) (0)
PS-028-Viral escape contributes to the failure of hepatitis D virus-specific CD8+ T-cells and drives evolution of HDV (2019) (0)
Out of sight for the endoscopist? Gastrointestinal bleeding after aortic repair (2022) (0)
Screening for HCV-specific T cell responses: THE USE OF PEPTIDE POOLS IMPAIR THE PROLIFERATION OF ANTIGEN SPECIFIC CD8 T-CELLS (2008) (0)
P094: Naturally occuring cross ‐ resistance mutation to boceprevir and telaprevir in a naive chronic hepatitis‐C patient: Presentation of a case (2015) (0)
448 Decline of HCV-specific CD8+ T cells during interferon-alpha therapy of acute hepatitis C (HCV): Role of apoptosis vs. differential regulation of chemokine receptors (2006) (0)
355 ENHANCED INTERFERON ALPHA-DEPENDENT TRAIL EXPRESSION BUT COMPRISED CYTOKINE PRODUCTION OF NK CELLS IN CHRONIC HEPATITIS C IN RELATION TO THE IL28B GENOTYPE (2013) (0)
P042: Hepatitis B surface proteins (SHBs, LHBs and MHBs) decline after stopping of nucleos(t)ide analogue therapy in HBeAg‐negative patients (2015) (0)
Rapid and sustained improvements of liver stiffness values in HCV-infected patients treated with direct-acting antiviral drugs (2016) (0)
1222ABT-450/r/Ombitasvir and Dasabuvir with Ribavirin Achieves High Sustained Virologic Response Rates Regardless of Baseline Characteristics: Pooled Analyses of the SAPPHIRE-I and SAPPHIRE-II Studies (2014) (0)
HIV & Hepatitis News New ARV Drugs: What’s in the Pipeline? 14th EACS Conference in Brussels AIDS Vaccine Congress in Barcelona HIV treatment guidelines 14th European AIDS conference: Update on ART HIV-associated lymphoma: Treatment update The price of antiretroviral therapy (2013) (0)
EFFICACY AND TOLERANCE OF TENOFOVIR DISOPROXIL FUMARATE PLUS EMTRICITABINE COMBINATION IN PATIENTS WITH CHRONIC HEPATITIS B - A EUROPEAN MULTICENTER STUDY (2010) (0)
Stigma or social support? Experiences of patients with chronic viral hepatitis in their social environment in Germany (2009) (0)
Genetic variability of hepatitis delta virus in Turkish and German patients: Implications for cellular immune responses (2003) (0)
[552] IV DRUG ABUSE IS MORE IMPORTANT FOR LIVER INJURY THAN HEPATITIS C VIREMIA IN YOUNG ANTI-HCV POSITIVE PATIENTS (2007) (0)
Influence of adipokines on cell entry, replication and virus production of Hepatitis C Virus (2013) (0)
P199: Mutational analysis of hepatitis E virus ORF1 ‘X‐domain’ identifies an evolutionary conserved macrodomain protein/Appr‐1''‐pase active‐site, critical for viral RNA replication in hepatoma cells (2015) (0)
677 FREQUENCY AND T-CELL RECEPTOR (TCR) REPERTOIRE OF HEPATITIS C VIRUS (HCV)-SPECIFIC CD8 T-CELLS IN HCV-SERONEGATIVE INDIVIDUALS (2010) (0)
Preexisting Hepatitis C Virus (HCV)-Specific CD8+ T Cells are Abundant in HCV-Seronegative Individuals and can Show Cross-Reactivity to Common Pathogens (2016) (0)
[Acute hepatitis C--therapy with interferon alpha-2b]]. (2002) (0)
P698 CLINICAL OUTCOME AFTER 2 YEARS FOLLOW-UP IN A COHORT OF EUROPEAN UNTREATED HEPATITIS B (HBV) INFECTED PATIENTS: A PROSPECTIVE LONGITUDINAL STUDY (ALBATROS STUDY) (2014) (0)
Sex Specific Differences in Nosocomial Infections in Patients with Decompensated Liver Cirrhosis (2021) (0)
Combination of everolimus and low-dose tacrolimus controls histological liver allograft injury as sufficiently as high-dose tacrolimus (2023) (0)
Broad and cross-genotype-specific T cell responses during acute hepatitis E virus infection (2015) (0)
Salvage therapies of autoimmune hepatitis limit proinflammatory immune cells while sparing regulatory T cells (2023) (0)
321 ANTI-HDV-IGM TESTING IN HEPATITIS DELTA REVISITED: CORRELATIONS WITH DISEASE ACTIVITY AND RESPONSE TO PEGYLATED INTERFERON ALFA-2A TREATMENT (2010) (0)
Hepatitis E virus replication and interferonresponse in human placental-derived cells (2018) (0)
Safety Comparison of 12- And 24-Week Treatments in HCV Genotype 1-Infected Patients With Cirrhosis: Results From Turquoise-II: 442 (2014) (0)
P0581 : Prediction of HBsAg seroclearance and HBsAg seroconversion in a cohort of inactive european hepatitis B (HBV) carriers: A prospective longitudinal study (albatros study) (2015) (0)
856 CLINICAL SIGNIFICANCE OF DRUG–DRUG-INTERACTIONS IN THE ERA OF DIRECT ACTING ANTIVIRAL AGENTS AGAINST HEPATITIS C – A REAL-WORLD EXPERIENCE (2013) (0)
651 VIROLOGICAL AND CLINICAL PATTERNS OF DELTA HEPATITIS IN CENTRAL EUROPE: A SINGLE CENTER EXPERIENCE WITH 255 PATIENTS (2008) (0)
Subject Index Vol. 30, Suppl. 1, 2012 (2012) (0)
Spontaneous clearance of hepatitis C viremia in the absence of humoral immunity and very low levels of cellular HCV-specific immunity (2006) (0)
729 ROLE OF BMI, AGE AND SEX FOR DISEASE SEVERITY IN ACUTE HEPATITIS C: ANALYSIS OF 254 PATIENTS FROM THE GERMAN HEP-NET ACUTE HCV COHORT (2008) (0)
Hepatitis C virus (HCV)-specific CD8 T-cells in HCV-seronegative individuals: Frequency and T-cell receptor repertoire (TCR) (2011) (0)
P: 47 Risk of Recurrent Hepatic Encephalopathy (HE) in Patients With Liver Cirrhosis: A German Registry Study (2019) (0)
EASL transitioning into the new decade. (2010) (0)
RIGINAL ARTICLES — LIVER , PANCREAS , ND BILIARY TRACT rognostic Implications of Lactate , Bilirubin , and Etiology in German atients With Acute Liver Failure (0)
Prädiktiver Wert von HCV-RNA Resultaten an frühen Zeitpunkten während der Behandlung mit Ledipasvir/Sofosbuvir von Patienten mit chronischer Hepatitis-C-Virusinfektion vom Genotyp 1: Ergebnisse aus dem Deutschen Hepatitis C-Register (DHC-R) (2017) (0)
Evaluation therapeutischer Plasmapherese bei donorspezifischen Antikörper assoziierten Komplikationen nach Lebertransplantation (2019) (0)
Die perkutane Leberblindpunktion als sichere diagnostische Methode mit guter Repräsentativität bei Patienten nach Lebertransplantation (2014) (0)
Untersuchung des Langzeitverlaufs von Patienten mit einer niedrig-replikativen chronischen Hepatitis B-Infektion, die keine antivirale Therapie erhalten: 2 Jahres-Daten einer deutschen prospektiven Studie (ALBATROS Studie) (2015) (0)
Transjugulärer intrahepatischer portosystemischer Shunt bei Patienten höheren Alters mit Leberzirrhose und therapierefraktärem Aszites - Wagen oder lieber bleiben lassen? (2020) (0)
28. Jahrestagung der Gesellschaft für Gastroenterologie in NRW e. V. (2019) (0)
Beständigkeit des virologischen Ansprechens zu Nachbehandlungswoche 12 (SVR12) bei HCV-Patienten nach Behandlung mit Ombitasvir/Paritaprevir/r und Dasabuvir mit Ribavirin in deutschen Studienzentren (2016) (0)
Pharmakokinetik von Meropenem in Aszites und Plasma bei PatientInnen mit nosokomialer spontan bakterieller Peritonitis und Leberzirrhose (2020) (0)
Entwicklung des Krankheitsbildes und der Behandlung von Patienten mit chronischer Hepatitis C-Infektion (HCV) unter Real-World Bedingungen in Deutschland: Erfahrungen aus 14 Jahren mit mehr als 16.000 Patienten (2017) (0)
Strategietreffen: Virushepatitis in Deutschland eliminieren – Was ist zu tun? (2023) (0)
Nachweis Hepatitis B spezifischer Immunantworten bei gesunden seronegativen Geschlechtspartnern von Patienten mit chronischer Hepatitis B Infektion (2008) (0)
Effektivität der „switch“-Strategie auf eine Tenofovir-(TDF)Monotherapie bei Patienten mit Nukleos(t)id-Analoga Resistenz: Eine Langzeitverlaufsdokumentation über bis zu 6 Jahre (2008) (0)
Detektion von portaler Hypertension durch Elastografie der Milz mittels ARFI ist der Elastografie der Leber unterlegen (2010) (0)
Zoonotisch übertragene Hepatitis E Virus als Ursache akuter und chronischer Hepatitiden bei Lebertransplantierten in Deutschland (2009) (0)
Elevated M30 serum levels allow the non-invasive detection of fibrotic NASH in NAFLD with low or intermediate FIB-4 (2023) (0)
Das Hepatitis C Nichtstrukturprotein 2 ist ein zusätzlicher Angriffspunkt für die durch Ciclosporin A vermittelte Hemmung der HCV RNA Replikation (2009) (0)
Erfahrungen in der Therapie der Hepatitis E Virusinfektion mit Ribavirin (2012) (0)
Eine mTor-basierte Immunsuppression vermindert die antivirale Effizienz von NS3/4A- und NS5A-Inhibitoren im HCV-Genotyp 1b in vitro (2018) (0)
Neue und aktuelle Therapieoptionen bei Hepatitis D (2021) (0)
Begrenztes Wissen über Hepatitis B und schlechte Durchimpfung von Verwandten von Hepatitis B Patienten in Deutschland (2009) (0)
Kenntnisse und Versorgung von Hepatitis-B-Infizierten in Deutschland (2012) (0)
8-wöchige Behandlung therapienaiver Patienten mit chronischer Hepatitis-C-Virusinfektion vom Genotyp 1 mit Ledipasvir/Sofosbuvir: Daten aus dem Deutschen Hepatitis C-Register (DHC-R) (2016) (0)
Steroide steigern die Hepatitis C Virus Infektiösität durch Modulation des Viruseintritts (2009) (0)
Hepatitis C Viruskinetik während einer Ribavirin Monotherapie: Ergebnisse einer randomisierten, partiell doppelt blind placebokontrollierten klinischen Studie (2011) (0)
Givosiran als neue therapeutische Option (2021) (0)
Impact of non-selective beta-blockers on survival and liver-related complications after TIPS-Insertion (2022) (0)
Verbesserte Pharmakodynamik und Pharmakokinetik nach intravenöser Applikation von Peg-Interferon alfa-2a bei Patienten mit Hepatitis C Genotyp 1 und Null Response auf eine Therapie mit Peg-Interferon alfa/Ribavirin (IVAN-Studie) (2013) (0)
Prognostische Biomarker für den Langzeitverlauf von Hepatitis Delta (2015) (0)
Hepatitis E – mehr als nur eine seltene Reisekrankheit! (2017) (0)
Akkurate und flexible Messung der Lebersteifigkeit mittels einer neuen Ultraschalltechnologie (ARFI) (2009) (0)
Hepatitis D (2020) (0)
Virale Hepatitiden: Andere virale Infektionen (2016) (0)
Therapie der Hepatitis C in Deutschland. Ergebnisse aus dem Deutschen Hepatitis C-Register 4 Jahre nach Zulassung der neuen direkt-antiviralen Substanzen (DAAs) (2018) (0)
LÄNGERES 10-JAHRES-ÜBERLEBEN VON LEBERTRANSPLANTIERTEN MIT AKTIVER GB-VIRUS-C INFEKTION (2007) (0)
Virusinaktivierung im Krankenhaus – wie stabil ist das Hepatitis C Virus? (2009) (0)
Therapie der Hepatitis C in Deutschland nach Zulassung der neuen direkt-antiviralen Substanzen: Erste Ergebnisse aus dem Deutschen Hepatitis C-Register (2015) (0)
Eingeschränkte TRAIL-abhängige Zytotoxizität myeloider dendritischer Zellen bei der chronischen Hepatitis C (2015) (0)
Die Elastografie der Milz mittels ARFI ist der Elastografie der Leber bei der Detektion von portaler Hypertension unterlegen (2009) (0)
Elastografie der Leber mittels einer neuen Ultraschalltechnologie (ARFI) (2010) (0)
Rolle der Hepatitis-B-Impfung in der Prävention des hepatozellulären Karzinoms (2021) (0)
Evaluation der Sicherheit und Verträglichkeit einer Tenofovir DF (TDF) Langzeit-Monotherapie bei Nukleos(t)id-Analoga-erfahrenen Patienten mit HBV Monoinfektion (2009) (0)
Statine bei Lebererkrankungen (2022) (0)
Detektion von portaler Hypertension durch Elastographie der Milz mittels ARFI ist der Elastographie der Leber unterlegen (2010) (0)
Deutsches Hepatitis C-Register: Aktuelle Auswertungen und ihre Konsequenzen (2018) (0)
Beeinflusst die UDCA-Therapie von PBC-Patienten inflammatorische Serumproteine? (2021) (0)
Von der Transmission bis zur Therapie - Hepatitis A und Hepatitis E - Epidemiologie und natürlicher Verlauf (2005) (0)
Ursodeoxycholsäure plus Bezafibrat bei PBC (2018) (0)
Fehlende Korrelation zwischen PD-1 Expression auf T-Zellen und klinischen Parametern in Patienten mit chronischer Hepatitis C Infektion (2008) (0)
DGVS Jahresrückblick 2021 (2021) (0)
Factors positively correlated with HBs seroconversion in chronic hepatitis B – a single center experience in a German cohort of 387 patients (2019) (0)
Virale Infektionen bei Lebertransplantierten (2020) (0)
Are psychometric tests helpful for the prediction of hepatic encephalopathy after TIPS insertion? (2022) (0)
Veränderungen der Hepatitis-C-Virus-Genotyp-1a/1b-Verteilung zwischen 2004 und 2018 in Deutschland – eine Analyse von 17093 Patienten aus verschiedenen Real-World-Registern (2021) (0)
Eine DAA Therapie vor Lebertransplantation hat keinen Einfluss auf das HCC Rekurrenz Risiko nach Lebertransplantation (2018) (0)
Sind sich Jugendliche über die Gefahren einer Hepatitis-B-Virusinfektion als Geschlechtskrankheit bewusst? (2012) (0)
Virale Hepatitiden – nach wie vor häufig und wichtig! (2021) (0)
Transglutaminase-2-Inhibitor zur Therapie der Zöliakie (2021) (0)
Die Grenzen des G-DRG-Systems bei der Abbildung von Komplexität in der Universitätsmedizin (2020) (0)
Prädiktion der Fibroseprogression bei Patienten mit niedrig-replikativer chronischer Hepatitis B (HBV) – Infektion: 3 Jahres-Daten einer prospektiven longitudinalen Studie (ALBATROS Studie) (2016) (0)
Klinischer und virologischer Verlauf einer akuten Hepatits A bei Patienten mit Hepatitis C: Geringes Risiko für eine fulminante Hepatitis und Suppression der HCV-Replikation (2006) (0)
HBV-Infektion in Deutschland – wie sind die Real-Life-Kosten? (2016) (0)
Statine bei Erkrankungen der Leber: Hopp oder top? (2021) (0)
Effektivität einer Tenofovir DF (TDF) Monotherapie in Abhängigkeit vorbestehender HBV-Resistenzmusterstationen bei Nukleosid/Nukleotid-Analoga-vorbehandelten Patienten (2009) (0)
Klinische Evaluation der ARFI-Elastografie mit der linearen Sonde (L9–4MHz): Vergleich mit der konvexen Sonde (C4–1MHz) und dem Fibroscan® zur Beurteilung der Leberfibrose bei Patienten mit chronischer HCV-Infektion (2013) (0)
Mortalität und ökonomische Auswirkungen der hepatischen Enzephalopathie bei Leberzirrhose in deutschen Krankenhäusern auf der Basis von G-DRG-Kostendaten (2019) (0)
Betablocker bei kompensierter Zirrhose (2019) (0)
EInfluss antiretroviraler Medikamente auf das Hepatitis C Virus (2013) (0)
Natürlicher Verlauf und Therapie der chronischen Hepatitis D (2007) (0)
Die frühe HDV-RNA Kinetik ist nicht prädiktiv für ein langfristiges Ansprechen auf eine PEG-Interferon-alpha-2a Therapie der Hepatitis Delta (2014) (0)
Erhöhte Komplikationsrate bei Patienten mit Donorspezifischen Antikörpern nach Lebertransplantation (2018) (0)
Intra-host diversity of hepatitis E virus polymerase during sofosbuvir treatment (2023) (0)
HBV-spezifische zelluläre Immunantworten bei der okkulten Hepatitis B nach Lebertransplantation (2006) (0)
Sodium taurocholate cotransporting polypeptide (hNTCP) Varianten beeinflussen den HDV Zelleintritt aber nicht den antiviralen Effekt von Myrcludex-B (2018) (0)
P121: Comparative proteomic analysis reveals alterations of Sec61 ER‐translocon at the acute and chronic stages of hepatitis C virus infection in a cell‐based reporter system (2015) (0)
PCR-Testung von Biopsien und Blutproben von lebertransplantierten Patienten mit „Graft Hepatitis“ auf CMV, EBV und HHV6 (2009) (0)
Chronische Virushepatitis - Update 2008 (Stand März 2008) (2008) (0)
Betablocker helfen bei Leberzirrhose (2019) (0)
Die perkutane Leberblindpunktion ist eine sichere diagnostische Methode mit guter Repräsentativität bei Patienten nach Lebertransplantation (2013) (0)
590 Economic evaluation of early monotherapy versus delayed combination therapy in patients with acute hepatitis C (2006) (0)
Gemeinsame Stellungnahme der Deutschen Gesellschaft für Gastroenterologie, Verdauungs- und Stoffwechselkrankheiten (DGVS) und der Deutschen Gesellschaft für Innere Medizin (DGIM) zur Ledipasvir / Sofosbuvir-Nutzenbewertung gemäß § 35a SGB V des G-BA (2015) (0)
Erstbeschreibung der T-Zellantwort gegen das gesamte Genom des Hepatitis E Virus (2016) (0)
Primär sklerosierende Cholangitis als unabhängiger Risikofaktor für das Auftreten von CMV-Infektionen bei Patienten nach Lebertransplantation (2018) (0)
Virale Infektionen bei Lebertransplantierten (2020) (0)
Lebertransplantierte als Risikogruppe für sonographisch gesicherte intestinale Invaginationen beim Erwachsenen (2010) (0)
Klinische Bedeutung der HBs Antigen-Konzentration bei Patienten mit chronischer HBV/HCV-Koinfektion (2009) (0)
24 Wochen Therapie mit Pegyliertem Interferon Alfa-2B bei Patienten mit akuter Hepatitis C Infektion (2004) (0)
Verlauf einer chronischen HCV-Infektion im Verlauf einer akuten Delta Hepatitis (2007) (0)
HCV — Eine Erkrankung auf dem — Weg zur Eradikation? (2018) (0)
The Addition of Ribavirin is Associated with a Significantly Reduced Quality of Life in Patients Treated with IFN-Free Direct-Acting Antiviral Therapy (2016) (0)
Erhöhte HEV-Seroprävalenz bei Patienten mit Autoimmunhepatitis (2010) (0)
Einsatz von Thrombopoetin-Rezeptor-Agonisten (TPO-RA) vor invasiven Eingriffen bei Patienten mit Leberzirrhose (2022) (0)
Hepatitis-A- und -E-Virus-Infektionen – Altes und Neues (2020) (0)
Statine bei Lebererkrankungen: gut oder schlecht? (2020) (0)
Ein vermeintliches hepatozelluläres Adenom stellt sich als intrahepatische Splenose heraus – ein Fallbericht (2021) (0)
Einzelnukleotid-Polymorphismen in der Promotorregion von Cyclophilin A haben keinen EInfluss auf den natürlichen Verlauf einer Hepatitis C Virusinfektion (2013) (0)
Gastroenterologische Komplikationen des Diabetes mellitus: Gastroparese (2021) (0)
Zytokin- und Chemokinmuster in Serum von hepatischen Venen differenzieren Patienten mit akutem Leberversagen von anderen Lebererkrankungen (2013) (0)
Die Baseline HCV RNA Viruslast als Entscheidungshilfe für die Behandlungsdauer mit Ledipasvir/Sofosbuvir bei HCV Genotyp-1-Patienten: Ergebnisse aus dem Deutschen Hepatitis C-Register (DHC-R) (2017) (0)
Aktuelles Management der Hepatitis Delta (2015) (0)
Sodium taurocholate cotransporting popypeptide variants modulate HDV entry according to their function as a bile acid transporter but do not influence the antiviral effect of Myrcludex-B (2018) (0)
Interferon-α-induzierte Reaktivierung einer Sarkoidose bei einer Patientin mit chronischer Hepatitis C (2010) (0)
Diagnostik und Therapie der Hepatitis Delta: neue Entwicklungen (2012) (0)
Gesamtfläche spontaner portosystemischer Shunts als unabhängiger Prädiktor (2020) (0)
Jahrespressekonferenz der DGVS 2021 (2021) (0)
Caspasen-Aktivität im Serum als prädiktiver Marker für das Therapieansprechen bei chronischer Hepatitis C Virus Infektion (2006) (0)
Sicherheit und Wirksamkeit direkt antiviraler Substanzkombinationen zur Behandlung der chronischen Hepatitis- C -Virusinfektion bei älteren Patienten (> 70 Jahre): Ergebnisse aus dem Deutschen Hepatitis C-Register (DHC-R) (2016) (0)
568 IMMUNOLOGICAL EVIDENCE FOR RESOLVED HBVINFECTION IN HEALTHY SERONEGATIVE SEXUAL PARTNERS OF PATIENTS WITH CHRONIC HBV INFECTION (2008) (0)
Patienten mit chronischer Hepatitis B nach Herztransplantation: Outcome nach 8-jähriger sequentieller Behandlung mit Nukleos(t)id-Analoga (2005) (0)
Dysfunctional adaptive immunity in liver cirrhosis and acute-on-chronic liver failure is characterized by aberrant immune checkpoint expression and diminished cytokine secretion in T cells (2020) (0)
Telomerasemutationen sind mit der Entstehung von Leberzirrhose assoziiert (2010) (0)
Prävalenz der HBV-Genotypen in Mittel–und Osteuropa (2007) (0)
Können Sie das Wort COVID noch hören? (2021) (0)
Drogenkonsum ist bedeutsamer für die Leberschädigung bei jungen anti-HCV positiven Patienten als die HCV Virämie (2006) (0)
Parvo-Virus B19 Infection: Evidence for intrahepatic long-term persistence but no association with disease progression in chronic hepatitis C (2008) (0)
Die HBsAg-Konzentration ist ein signifkanter Prädiktor für den Krankheitsverlauf bei Patienten mit niedrig-replikativer chronischer Hepatitis B (HBV)-Infektion (2013) (0)
Elastographie der Leber mittels einer neuen Ultraschalltechnologie (ARFI) (2010) (0)
Phänotypische Charakterisierung von HCV-spezifischen CD8+ T-Zellen nach HCV-Peptidimpfung vs. akute und chronische Hepatitis C (2006) (0)
Prädiktion von HBsAg Verlust und HBsAg Serokonversion bei Patienten mit niedrig-replikativer chronischer Hepatitis B (HBV) – Infektion: 2 Jahres-Daten einer deutschen prospektiven longitudinalen Studie (ALBATROS Studie) (2015) (0)
Sicherheit und Wirksamkeit interferonfreier antiviraler Therapien in der Behandlung fortgeschrittener HCV-assoziierter Leberzirrhose: Ergebnisse aus dem Deutschen Hepatitis C-Register (DHC-R) (2016) (0)
Thrombozytenzahl, Albumin und Bilirubin identifizieren Patienten mit chronischer Hepatitis C Zirrhose mit hohem Risiko für ein Therapieversagen und schwerwiegende Nebenwirkungen während einer Triple-Therapie mit Boceprevir oder Telaprevir (2014) (0)
Longterm treatment with pegylated interferon-alfa2b reduces hepatocellular carcinoma incidence and prevents clinical complication in hepatitis C liver cirrhosis–an interim analysis of a multicenter trial (2007) (0)
2-Jahresdaten der Telbivudin GLOBE Studie: Wirksamkeit, Verträglichkeit und Prädiktoren des Behandlungserfolgs bei HBeAg-negativen Patienten mit chronischer Hepatitis B (2007) (0)
Bedeutung der Histologie für die Diagnose und Prognose chronischer Lebererkrankungen aus internistischer Sicht (2006) (0)
Massiver Ikterus unter Interferon/Ribavirinbehandlung bei Hepatitis C: behandeln oder abbrechen? – eine genetische Antwort (2006) (0)
Seroprävalenz von Antikörpern/Antigen gegen Hepatitisviren A, B, C, D und E bei Flüchtlingen in Deutschland im Jahr 2015 (2016) (0)
Häufigere spontane Ausheilung einer akuten HCV-Genotyp 3-Infektion (2004) (0)
Langzeitnachbeobachtung nach IFN-freier Therapie bei fortgeschrittener HCV-assoziierter Leberzirrhose: Kontinuierliche Verbesserung der Leberfunktionsparameter – Ergebnisse aus dem Deutschen Hepatitis C-Register (DHC-R) (2017) (0)
Pulmonale Komplikationen einer Lebererkrankung sicher erkennen (2019) (0)
Sequentielle Therapie mit Interferon alfa und Lamivudin als Konzept für die Therapie der chronischen Hepatitis B: Höhere Chance der HBs-Serokonversion? (2006) (0)
Slow progressive very late-onset LAL-D: the importance of liver biopsy (2020) (0)
Soluble inflammatory molecules do not completely normalize despite early treatment of acute symptomatic hepatitis C (2020) (0)
EXCHANGE-2: investigating the efficacy of add-on plasma exchange as an adjunctive strategy against septic shock—a study protocol for a randomized, prospective, multicenter, open-label, controlled, parallel-group trial (2023) (0)
Letter: the role of direct‐acting anti‐virals in determining the risk of hepatocellular carcinoma development in patients with hepatitis C virus‐induced cirrhosis—Authors' reply (2018) (0)
NK cells regulate LSEC to promote the HBV-specific T cells response (2020) (0)
Reaching the unreachable: Strategien für die effektive HCV Behandlung bei Patienten mit fortgesetztem intravenösen Drogengebrauch - eine Real-World Erfahrung (2021) (0)
Reply (2012) (0)
The Interplay of antigen and antibody in HEV infection (2023) (0)
Autoimmune hepatitis in young Somalian men – experience from a German tertiary care center (2023) (0)
Health related quality of life of patients in opioid substitution therapy at the beginning of hepatitis C treatment - Data from the German Hepatitis C-Registry (2021) (0)
Liver Transplantation After Organ Donation Due to Hydrogen Sulfide Intoxication: Report of the First Case. (2022) (0)
Low free triiodothyronine (fT3) is associated with advanced fibrosis in non-alcoholic steatohepatitis (NASH) (2019) (0)
Prevalence and clinical presentation of HDV infection in Central Europe in relation to country of birth (2007) (0)
Treatment strategies for patients with decompensated liver cirrhosis due to HCV infection – Antiviral treatment or liver transplantation first? (2018) (0)
Persistent long-term risk of liver related complications in HCV patients after antiviral therapy - Data from the German Hepatitis C-Registry (2021) (0)
Long-term course of a patient with overlap hepatitis C and IgG4-related cholangitis (2020) (0)
Viral escape contributes to the failure of hepatitis D virus (HDV)-specific CD8+ T cells and drives population-level evolution of HDV (2019) (0)
Establishment of a transgenic, single-nodule model of liver cancer in a fibrotic background (2021) (0)
Hepatic steatosis in Crohn's disease: associations with anti-TNFα treatment, dysbiosis, and FGF-19. (2020) (0)
Antivirals in Acute Hepatitis C (2011) (0)
Comment on: Effects of cyclosporine on human dendritic cell subsets. Author's reply (2005) (0)
Peritoneal cytokines of patients with decompensated liver cirrhosis drive NK and T cells towards an activated phenotype (2021) (0)
Role of autophagy in amiodarone-mediated hepatotoxicity (2021) (0)
The differential phenotype and functionality of CMV- and EBV-specific CD8 T cells in patients with chronic hepatitis C is associated with an altered plasma cytokine milieu (2015) (0)
Improvement of quality of life after TIPS insertion (2021) (0)
P545 Does gender matter? Gender-related nutritional behaviour, disease activity and quality of life in patients with inflammatory bowel diseases (2023) (0)
P071: Viral hepatitis A, B and C in an Afro‐Brazilian community ten years after the first epidemiological and molecular survey (2015) (0)
Diversity of clinical presentation and virological characteristics of hepatitis delta: The hepatitis Delta International network (HDIN) (2016) (0)
Hepatitis E seroprevalences in pregnant and non-pregnant women in a southern region of Brazil (2016) (0)
CD103 identifies an ascites-resident NK cell subset with reduced effector capacity that originates in the intestine (2023) (0)
Markers of cell death predict therapy response in patients with cirrhosis and hepatorenal syndrome (2022) (0)
Cirrhosis and acute-on-chronic liver failure are linked with aberrant expression of co-stimulatory markers on T-cells (2020) (0)
Barriers to hepatitis C virus elimination in Germany: why aren’t diagnosed patients initiating therapy? (2020) (0)
Efficacy of bulevirtide as monotherapy for chronic hepatitis D (CHD): Week 48 results from an integrated analysis (2023) (0)
Prognostic serum biomarkers for graft survival after liver transplantation in hepatitis C patients (2013) (0)
Hepatitis D: Looking Back, Looking Forward, Seeing the Reward and the Promise (2023) (0)
Immunological scars after cure of hepatitis C virus infection: Long-HepC? (2023) (0)
Development and performance of prototype serologic and molecular tests for hepatitis delta infection (2018) (0)
Reply to Letter to the Editor. (2017) (0)
Sofosbuvir plus velpatasvir for 8 weeks in patients with acute hepatitis C: The HepNet acute HCV-V study (2022) (0)
Does response to antiviral therapy affect the clinical long-term outcome of hepatitis delta? (2016) (0)
397 LONGITUDINAL ANALYSIS OF QUANTITATIVE SERUM HBSAG IN HBV/HIV COINFECTED PATIENTS (2011) (0)
Declining Numbers of Hepatitis C Virus-Associated Liver Transplantations in Germany. (2021) (0)
Diagnosis and managment of membranous Budd-Chiari syndrome (2008) (0)
P104: Serum biomarker profile can predict the outcome of acute HCV infection (2015) (0)
TNFR1 inhibition reduces lipogenesis and improves insulin resistance and fibrosis in NAFLD (2022) (0)
The association of 2B4 up-regulation and SAP down-regulation indicates exhaustion of virus-specific CD8+ T cells (2011) (0)
IMMUNOSUPPRESSIVE AGENTS AND THEIR INFLUENCE ON HCV RNA REPLICATION AND INFECTIVITY IN VITRO: 1942 (2008) (0)
PS-030-Cure of hepatitis C virus has limited impact on the functional and mitochondrial impairment of HCV-specific CD8+ T-cell responses (2019) (0)
Exacerbation d’infection par le virus de l’hépatite E au cours d’un traitement par anti-TNFα (2017) (0)
Treating hepatitis D with bulevirtide - Real-world experience from 114 patients. (2023) (0)
Risk factors for HBV induced liver cirrhosis (2003) (0)
Distinct profiles and kinetics of soluble inflammatory markers in patients with acute and chronic HCV-infections and SARS-CoV-2-infections: Implications for the long-term consequences of viral infections? (2023) (0)
Global Real-World Evidence of Sofosbuvir/Velpatasvir as a Highly Effective Treatment and Elimination Tool in People with Hepatitis C Infection Experiencing Mental Health Disorders (2022) (0)
Reply: (2006) (0)
IL-12 rather than immune checkpoint inhibitors contribute to the functional restoration of hepatitis D virus-specific T-cells (2015) (0)
369 HEPATITIS DELTA VIRUS RNA DETECTION AND QUANTIFICATION: ISSUES WITH STANDARDIZATION AND NEEDS FOR CLINICAL PRACTICE (2011) (0)
Does Antiviral Treatment Affect the Clinical Long-Term Outcome of Hepatitis Delta? (2016) (0)
Strong decline of intrahepatic HDV markers and signs of liver inflammation after 48 weeks of treatment with Bulevirtide in chronic hepatitis D patients: Combined intrahepatic results from the clinical trials MYR203 and MYR301 (2023) (0)
Acute CMV-colitis in a patient with a history of ulcerative colitis. (2003) (0)
111 NEW APPROACH FOR THE IDENTIFICATION OF REPLICATION COMPETENT HCV ISOLATES DERIVED FROM PATIENT SERA (2010) (0)
Impact of Dynamic Viral and Biochemical Parameters on Progression of Liver Fibrosis in a Cohort of Inactive European Hepatitis B (HBV) Carriers: A Prospective Longitudinal Study (Albatros Study) (2016) (0)
Vaccine to Inhibit Autochthonous Transmission of Hepatitis (VaccinATE) (2023) (0)
21 FUNCTIONAL RELEVANT TELOMERASE MUTATIONS ASSOCIATE WITH CIRRHOSIS FORMATION IN PATIENTS WITH CHRONIC LIVER DISEASE (2010) (0)
Cost of illness of hepatitis c in germany: A retrospective multicenter analysis (2013) (0)
Impact of steroid withdrawal on subclinical graft injury after liver transplantation: A propensity score-matched cohort analysis (2023) (0)
ASIC — LIVER , PANCREAS , AND BILIARY RACT lucocorticosteroids Increase Cell Entry by Hepatitis C Virus (0)
Long-Term Liver-Related Outcomes in Hepatitis B and D Co-Infected Patients in Sweden (2018) (0)
Update on the Management of HBV-HDV Coinfection (2012) (0)
539 TGFB EXPRESSION IN CD4+/CD25+/FOXP3+/CD127LOW CELLS MAY HELP TO DISTINGUISH HCV HEPATITIS FROM REJECTION IN LIVER TRANSPLANT RECIPIENTS (2011) (0)
Hepatitis C virus genotypes are associated with distinct intestinal microbial community structures (2017) (0)
632 Hepatitis C virus infection in a juvenile prison: High prevalence of HCV among immigrants from the former Soviet Union to Germany (2003) (0)
BISCIT: Biliary interventions in critically ill patients with secondary sclerosing cholangitis—a study protocol for a multicenter, randomized, controlled parallel group trial (2023) (0)
Hepatitis A virus superinfection suppresses hepatitis C virus replication and may lead to spontaneous HCV clearance (2002) (0)
P1212 USE OF BASELINE FIBROSCAN TO PREDICT EFFICACY AND SAFETY OF TREATMENT FOR 1143 PATIENTS IN THE TELAPREVIR EARLY ACCESS PROGRAMME (2014) (0)
86 INDIVIDUAL HIERARCHIES OF CO-STIMULATORY RECEPTORS ON HCV-SPECIFIC CD8+ T-CELLS IN CHRONIC HEPATITIS C (2010) (0)
complicationsviral hepatitis C: efficacy, side effects, and (2007) (0)
P140: Drug‐drug interactions with novel all oral interferon free antiviral agents ‐ all issues solved? (2015) (0)
Treatment with bulevirtide improves patient-reported outcomes in patients with chronic hepatitis delta: An exploratory analysis of a Phase 3 trial at 48 weeks (2022) (0)
Hepatitis E in Haematological Patients in Europe: A Multicentre Study (2016) (0)
P689 DIFFERENTIATION OF PATIENTS WITH HBeAg NEGATIVE HEPATITIS VERSUS HBeAg NEGATIVE INACTIVE CARRIER STATUS BY SERUM CYTOKINES AND CHEMOKINES (2014) (0)
Histopathology of chronic Hepatitis E (2015) (0)
Author Correction: Development and performance of prototype serologic and molecular tests for hepatitis delta infection (2020) (0)
897 CONSENSUS RECOMMENDATIONS FOR VIROLOGIC NOMENCLATURE IN DAA CLINICAL TRIALS (2012) (0)
Virological heterogenity of hepatitis delta among Vietnamese populations (2018) (0)
HIV Disclosure Measures (2018) (0)
P1176 INCIDENCE AND RISK FACTORS FOR INFECTIONS DURING INTERFERON-BASED TREATMENT OF CHRONIC HEPATITIS C PATIENTS WITH ADVANCED HEPATIC FIBROSIS (2014) (0)
Clinical and molecular characterization of the human kidney as extrahepatic site of hepatitis E virus infection (2020) (0)
Machine learning identifies immune profile to predict virological relapse after stopping nucleos(t)ide analogue therapy in HBeAg negative chronic hepatitis B (2020) (0)
Significance of HBsAg and HDVRNA levels in patients with delta hepatitis recruited in the Hep-Net/International HDV intervention trial (2006) (0)
Increased seroprevalence of HAV and parvovirus B19 in children and of HEV in adults at diagnosis of autoimmune hepatitis (2018) (0)
Successful triple therapy of patients with chronic hepatitis C genotype 1 infection leads to significant improvement of non-invasive liver fibrosis tests (2014) (0)
Entecavir efficacy and safety in patients >= 50 years of age (2012) (0)
Abstract 2498: The MVA viral platform for the treatment of cancer and chronic infectious diseases: Clinical experience from four randomized controlled phase II studies (2015) (0)
PGI19 Costs and Effects of Dual Therapy With Pegylated Interferon and Ribavirin in Patients With Chronic Hepatitis C in Germany (2012) (0)
MicroRNAs modulate SARS-CoV-2 infection in primary human hepatocytes by regulating the entry factors ACE2 and TMPRSS2 (2022) (0)
626 COMPREHENSIVE PHENOTYPIC ANALYSIS OF NK CELLS IN ACUTE HEPATITIS C VIRUS INFECTION (2008) (0)
Adefovir treatment failure is not associated with low serum drug levels (2010) (0)
Corrigendum: Increasing Number of Individuals Receiving Hepatitis B nucleos(t)ide Analogs Therapy in Germany, 2008–2019 (2022) (0)
Early on treatment detection of nucelos(t)ide analogue resistant minor variants of Hepatitis B virus (HBV) with ultra deep-pyrosequencing (UDPS) in chronic hepatitis B(CHB) patients (2013) (0)
Non-Invasive Clinical Scores to Identify Liver Fibrosis in Hepatitis Delta Patients (2016) (0)
Clinical value and safety of liver biopsies in patients transplanted for hepatitis C virus‐related end‐stage liver disease (2014) (0)
P215: Exacerbation of hepatitis E virus infection during anti‐TNFα treatment (2015) (0)
Comprehensive phenotyping of natural killer cells in acute and chronic viral hepatitis (2013) (0)
Post-treatment elevated gamma-glutamyl transferase is the best predictor for future outcomes in HCV patients achieving sustained virological response-data from the german hepatitis C-registry (DHC-R) (2022) (0)
O232: Hepatitis E: are serologic tests good enough and reliable? (2013) (0)
EASL Recognition Awardee for 2014: Prof. Geoff-Dusheiko. (2014) (0)
Characterization of T cell responses after stopping HBV therapy with nucleos(t)ide analogues (NA) in HBeAg-negative patients (2016) (0)
In reply. (2015) (0)
Experimental Hepatitis E Infection in Pigs (2009) (0)
P103: Effect of endogenous ligands of the high densitiy lipoprotein‐receptor scavenger receptor class B type I on the replication cycle of the hepatitis C virus (2015) (0)
Immune escape pathways from the HBV core18-27 CD8 T cell response are driven by individual HLA class I alleles (2022) (0)
Hepatitis B vaccine non-response and occult hepatitis B virus infection (2008) (0)
819 IMPROVED PHARMACODYNAMICS AND PHARMACOKINETICS AFTER INTRAVENOUS APPLICATION OF PEG-INTERFERON alfa-2a 180 μg IN CHRONIC HEPATITIS C GENOTYPE 1 NULLRESPONDERS TO PEGINTERFERON/RIBAVIRIN. THE IVAN STUDY (2013) (0)
84 ADAPTIVE HEV-SPECIFIC T-CELL RESPONSES ARE ASSOCIATED WITH CONTROL OF HEV INFECTION (2011) (0)
IFN-alpha induced IFN-gamma production of NK cells is not inhibited but enhanced by adenosine (2009) (0)
Global real-world evidence of sofosbuvir/velpatasvir (SOF/VEL) as a highly effective treatment in underserved patient populations because of mental health disorders, incarceration or homelessness (2022) (0)
Limited value of HBV-RNA levels for the prediction of relapse after discontinuation of nucleos (t)ide analogue therapy in HBe antigen negative chronic hepatitis B patients (2022) (0)
1013 High SVR Rates Despite Multiple Negative Predictors in Genotype 1 Patients Receiving Ombitasvir/Paritaprevir/R, Dasabuvir With or Without Ribavirin for 12 and 24 Weeks: Integrated Analysis of Six Phase 3 Trials (2015) (0)
[Viral hepatitis and pregnancy]. (1974) (0)
Targeting epigenetic imprints to modulate HBV-specific T cell responses (2023) (0)
Rapid and Sustained Improvements of Liver Stiffness Values in HCV-Infected Patients Treated with Direct Antiviral Drugs (2016) (0)
Variants in the human PPIA gene render host cells refractory to hepatitis C virus infection by destabilization of the essential host factor cyclophilin A (2012) (0)
334.6: Porcine SLA-Specific Car Treg Enable Xenotransplantation in the Absence of Immunosuppression (2022) (0)
404.1: Membrane-Bound IL-2 Improves Expansion, Survival, Phenotype and Function of Car Tregs and Confers Resistance to Calcineurin-Inhibitors (2022) (0)
445 Function and phenotype of peptide-vaccine induced HCV specific CD8+ T cells vs. acute and chronic hepatitis C (2006) (0)
How to interpret borderline HCV antibody test results? A comparative study investigating four different anti-HCV assays (2013) (0)
896 INHIBITORY MECHANISM OF PEPTIDE POOLS ON THE PROLIFERATION OF ANTIGEN-SPECIFIC CD8+ T CELLS (2009) (0)
SUPPLEMENT (1966) (0)
P.076 The cost of hepatitis B in Germany (2006) (0)
Effect of Hepatitis B virus on Steatosis in Hepatitis C virus co-infected subjects: a multi-center study and systematic review (0)
467 LONGTERM BENEFITS OF SUSTAINED VIROLOGICAL RESPONSE (SVR) IN PATIENTS WITH CHRONIC HEPATITIS C (CHC) VIRUS INFECTION: THE GERMAN LOTOS STUDY (2011) (0)
1240 CHRONIC HEPATITIS E IN LUNG TRANSPLANT RECIPIENTS (2013) (0)
Chronic hepatitis E in patients with CVID in Germany (2012) (0)
Splenectomy induces biochemical remission and regeneration in experimental murine autoimmune hepatitis (2022) (0)
Telomere shortening is a prognostic factor in chronic hepatitis C virus infection (2008) (0)
Autophagy alleviates amiodarone-induced hepatotoxicity (2020) (0)
P918 miRNA BASED SCORE FOR THE CORRECT DIAGNOSIS OF REJECTION VS RECURRENT HEPATITIS C IN LIVER TRANSPLANTED PATIENTS (2014) (0)
Evolution of hepatitis C virus genotype 1a vs 1b distribution reflects profound changes in HCV epidemiology in Germany - analysis of 17,093 patients from five consecutive registries including the German hepatitis C-registry (DHC-R) (2020) (0)
416 PREDICTION OF ACTIVE HBV-CARRIER STATUS IN A COHORT OF EUROPEAN UNTREATED HBeAg NEGATIVE PATIENTS: A PROSPECTIVE LONGITUDINAL STUDY (2013) (0)
High tolerance of hepatitis E virus towards alcohol-based disinfectants (2022) (0)
Eleventh International Congress on Drug Therapy in HIV Infection (2012) (0)
SAT-437-An mTor-based immunosuppression reduces the antiviral efficacy of NS3/4A and NS5A inhibitors for HCV genotype 1b treatment in vitro (2019) (0)
FRI-370-Application of an extended-release tacrolimus formulation allows dose reduction and stabilizes graft function after liver transplantation (2019) (0)
Alcoholic liver disease is associated with a poorer survival after radioembolisation for hepatocellular carcinoma (2020) (0)
O313: How do we treat acute HCV when we don't have any trial data? (2014) (0)
Characterization of viral replication in different Hepatitis B virus-transgenic mice and its impact on antiviral signalling in vivo (2023) (0)
25 INTRAHEPATIC HHV6 DNA LEVELS BUT NOT EBV OR CMV ARE ASSOCIATED WITH GRAFT SURVIVAL AFTER LIVER TRANSPLANTATION (2010) (0)
BASIC—LIVER, PANCREAS, AND BILIARY TRACT Glucocorticosteroids Increase Cell Entry by Hepatitis C Virus (2010) (0)
P070: Cytokine patterns of patients with HCV/HBV co‐infection (2015) (0)
LATE-BREAKER POSTER ABSTRACTS (2012) (0)
[In Process Citation]. (2014) (0)
Real-world effectiveness and safety of glecaprevir/ pibrentasvir for the treatment of patients with chronic HCV infection: A meta-analysis Graphical (2020) (0)
Hepatitis B surface antigen induces nuclear accumulation of YAP, thereby driving BMI1-associated hepatocarcinogenesis (2022) (0)
Delayed decrease of splenic stiffness in chronic hepatitis C virus patients receiving direct-acting antivirals (2017) (0)
Bulevirtide 2 mg/day monotherapy in patients with chronic hepatitis delta with or without cirrhosis: a multicenter european cohort real-life study (2022) (0)
Incidence of alpha-fodrin antibodies in patients with chronic hepatitis C infection and sicca syndrome: a prospektive single-center study (2008) (0)
HLA-A2 restricted CD8+ T cell immune hierarchy towards full length hepatitis E virus for T cell-based therapy in chronic HEV (2018) (0)
[284] ADENOSINE AND INTERFERON ALPHA SYNERGISTICALLY INCREASE INTERFERON GAMMA PRODUCTION OF PBMC VIA THE A3-RECEPTOR (2007) (0)
Qualitiy of life-scores improve after 96 weeks of PEG-IFNa-2a treatment of hepatitis D: an analysis of the HIDIT-II trial (2023) (0)
Liver biopsy post liver transplantation for HCV-related end stage liver disease: Clinical value and risk factors for graft hepatitis and rejection (2013) (0)
Students’ guide to documentation in clinical trials (2022) (0)
Table of contents (2017) (0)
Poor clinical and virological outcome of nucleos(t)ide therapy in HBV/HDV co-infected patients (2020) (0)
Sofosbuvir plus velpatisvir for 8 weeks in patients with acute hepatitis C: multicenter, single arm, phase 2 study (The HepNet acute HCV-V study) (2022) (0)
Imprints of post-liver transplantation: HCV recurrence on immune cell compartment persist despite achieving therapy-induced SVR (2020) (0)
Improved pharmacodynamics and pharmacokinetics after i.v. application of peginterferon alfa‐2a in hepatitis C null responders (2015) (0)
P0667 : Interruption of nucleos(t)ide analogue therapy for HBeAg-negative chronic hepatitis B – A new concept to achieve HBsAg decline? (2015) (0)
Hepatitis E ORF2 Antigen Levels Differentiate between Acute and Chronic Course of Infection (2016) (0)
772 SINGLE NUCLEOTIDE POLYMORPHISMS IN HUMAN CYCLOPHILIN A AND THEIR INFLUENCE ON HCVRNA REPLICATION IN VITRO (2011) (0)
Limited recirculation of cytotoxic NK cells during normal homeostasis in humans (2019) (0)
Role of the CD26/ADA/adenosine system in viral and autoimmune chronic liver disease (2007) (0)

This paper list is powered by the following services:

What Schools Are Affiliated With Heiner Wedemeyer?

Heiner Wedemeyer is affiliated with the following schools:

Hannover Medical School
Queen Mary University of London
Karolinska Institute
University of Duisburg-Essen

Heiner Wedemeyer's Academic­Influence.com Rankings

Heiner Wedemeyer's Degrees

Why Is Heiner Wedemeyer Influential?

Heiner Wedemeyer's Published Works

Published Works

What Schools Are Affiliated With Heiner Wedemeyer?

Heiner Wedemeyer's AcademicInfluence.com Rankings